

# CITATION REPORT

List of articles citing

**Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)**

**DOI: 10.1016/j.opthta.2013.03.046**  
**Ophthalmology, 2013, 120, 2292-9.**

**Source:** <https://exaly.com/paper-pdf/55951417/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
777	Characterizing relationship between optical microangiography signals and capillary flow using microfluidic channels. <b>2016</b> , 7, 2709		
776	Characterizing relationship between optical microangiography signals and capillary flow using microfluidic channels. <b>2016</b> , 7, 2709		
775	Characterizing relationship between optical microangiography signals and capillary flow using microfluidic channels. <b>2016</b> , 7, 2709		
774	Photodynamic therapy for polypoidal choroidal vasculopathy. <i>Progress in Retinal and Eye Research</i> , <b>2013</b> , 37, 182-99	20.5	69
773	Methallothionein-3 contributes to vascular endothelial growth factor induction in a mouse model of choroidal neovascularization. <b>2013</b> , 5, 1387-96		13
772	SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. <b>2013</b> , 54, 5797-806		31
771	One-year outcome of ranibizumab for neovascular age-related macular degeneration: a thorough analysis in a real-world clinical setting. <b>2014</b> , 24, 396-401		17
770	A delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration. <b>2014</b> , 2014, 595132		7
769	Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering. <b>2014</b> , 2014, 510285		39
768	Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration. <b>2014</b> , 8, 717-23		10
767	Interleukin-17 induces angiogenesis in human choroidal endothelial cells in vitro. <b>2014</b> , 55, 6968-75		23
766	Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients. <i>Eye</i> , <b>2014</b> , 28, 1218-22	4.4	14
765	Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography. <b>2014</b> , 98, 956-60		22
764	Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity. <b>2014</b> , 41, 925-43		43
763	IL-18 is not therapeutic for neovascular age-related macular degeneration. <b>2014</b> , 20, 1372-5		31
762	Funduscopy results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain. <i>BMC Ophthalmology</i> , <b>2014</b> , 14, 138	2.3	4
761	Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. <i>Retina</i> , <b>2014</b> , 34, 1308-15	3.6	55

760	Trends in age-related macular degeneration management in Singapore. <b>2014</b> , 91, 872-7		9
759	Long-term longitudinal study of patients treated with ranibizumab for neovascular age-related macular degeneration. <b>2014</b> , 25, 158-63		19
758	Abstracts of the European Vitreoretinal update 14th Euretina Congress, 2014, London, England. <i>Ophthalmologica</i> , <b>2014</b> , 232 Suppl 1, 1-36	3.7	12
757	Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. <b>2014</b> , 19, 37-48		333
756	Current Strategies for the Management of Treatment-Resistant Neovascular Age-Related Macular Degeneration. <b>2014</b> , 2, 6-13		3
755	Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels. <b>2014</b> , 28, 2369-79		40
754	The photosynthetic eukaryote <i>Nannochloris eukaryotum</i> as an intracellular machine to control and expand functionality of human cells. <b>2014</b> , 14, 2720-5		7
753	Glycobiology of ocular angiogenesis. <b>2014</b> , 24, 1275-82		10
752	Genistein attenuates choroidal neovascularization. <b>2014</b> , 25, 1177-1182		6
751	A safety evaluation of ranibizumab in the treatment of age-related macular degeneration. <b>2014</b> , 13, 1259-70		12
750	Vasoprotective effect of PDGF-CC mediated by HMOX1 rescues retinal degeneration. <b>2014</b> , 111, 14806-11		21
749	Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. <b>2014</b> , CD005139		155
748	Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2014</b> , 252, 1705-9	3.8	56
747	Doxycycline inhibits polarization of macrophages to the proangiogenic M2-type and subsequent neovascularization. <b>2014</b> , 289, 8019-28		54
746	Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). <b>2014</b> , 98, 1144-67		308
745	The role of proteases and inflammatory molecules in triggering neovascular age-related macular degeneration: basic science to clinical relevance. <b>2014</b> , 164, 179-92		9
744	Driving habits in older patients with central vision loss. <i>Ophthalmology</i> , <b>2014</b> , 121, 727-32	7.3	33
743	Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen. <b>2014</b> , 98, 1197-200		13

742	Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid. <b>2014</b> , 28, 129-33		21
741	Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy. <b>2014</b> , 158, 337-44		16
740	A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. <b>2014</b> , 98 Suppl 1, i22-27		54
739	Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. <b>2014</b> , 158, 724-732.e2		57
738	Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. <b>2014</b> , 158, 537-43.e2		46
737	Neuropilin-1 enforces extracellular matrix signalling via ABL1 to promote angiogenesis. <b>2014</b> , 42, 1429-34		15
736	Effect of switching therapy to pegaptanib in eyes with the persistent cases of exudative age-related macular degeneration. <b>2014</b> , 93, e116		8
735	Stereotactic low voltage x-ray radiotherapy for treating neovascular age-related macular degeneration. <b>2014</b> , 9, 153-158		
734	Diffusion of anti-VEGF injections in the Portuguese National Health System. <i>BMJ Open</i> , <b>2015</b> , 5, e009006		6
733	Best-corrected visual acuity and retinal thickness are associated with improved cortical visual processing in treated wet AMD patients. <i>Acta Ophthalmologica</i> , <b>2015</b> , 93, 621-5	3.7	4
732	What Does Genetics Tell Us About Age-Related Macular Degeneration?. <b>2015</b> , 1, 73-96		18
731	Incidence of outer retinal tubulation in ranibizumab-treated age-related macular degeneration. <i>Retina</i> , <b>2015</b> , 35, 1166-72	3.6	13
730	MULTIMODAL IMAGING FINDINGS AND MULTIMODAL VISION TESTING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2015</b> , 35, 1292-302	3.6	21
729	ARE INTRAVITREAL INJECTIONS WITH ULTRATHIN 33-G NEEDLES LESS PAINFUL THAN THE COMMONLY USED 30-G NEEDLES?. <i>Retina</i> , <b>2015</b> , 35, 1778-85	3.6	23
728	TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH RANIBIZUMAB COMBINED WITH KETOROLAC EYEDROPS OR PHOTODYNAMIC THERAPY. <i>Retina</i> , <b>2015</b> , 35, 1547-54	3.6	13
727	A Decade of Anti-VEGF Drugs in Ophthalmology- Successes and Challenges. <b>2015</b> , 06,		1
726	Restoration of Outer Retinal Layers After Aflibercept Therapy in Exudative AMD: Prognostic Value. <b>2015</b> , 56, 4129-34		29
725	A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis. <b>2015</b> , 9, 1759-66		27

724	The role of aflibercept in the management of diabetic macular edema. <b>2015</b> , 9, 4389-96		8
723	Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration. <i>Journal of Clinical Medicine</i> , <b>2015</b> , 4, 1380-402	5.1	40
722	Suppression of Laser-Induced Choroidal Neovascularization by the Oral Medicine Targeting Histamine Receptor H4 in Mice. <b>2015</b> , 4, 6		5
721	Baseline Predictors for Good Versus Poor Visual Outcomes in the Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Therapy. <b>2015</b> , 56, 5040-7		36
720	Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development. <b>2015</b> , 9, 1001-15		24
719	The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0133628	3.7	23
718	Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections. <b>2015</b> , 2015, 820605		7
717	Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration. <b>2015</b> , 2015, 412903		10
716	Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration. <b>2015</b> , 9, 353-66		34
715	IL-18 Immunotherapy for Neovascular AMD: Tolerability and Efficacy in Nonhuman Primates. <b>2015</b> , 56, 5424-30		25
714	[Change of therapy from ranibizumab to aflibercept for recurrent or persistent exudative age-related macular degeneration]. <b>2015</b> , 112, 435-43		3
713	The genetics of age-related macular degeneration (AMD)--Novel targets for designing treatment options?. <b>2015</b> , 95, 194-202		31
712	Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. <i>Ophthalmology</i> , <b>2015</b> , 122, 803-8	7.3	91
711	Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: "real life" long-term outcome. <i>BMC Ophthalmology</i> , <b>2015</b> , 15, 39	2.3	7
710	Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. <i>BMC Ophthalmology</i> , <b>2015</b> , 15, 40	2.3	17
709	Imatinib may be ABL to improve anti-angiogenic therapy. <b>2015</b> , 2, e968034		3
708	UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12. <b>2015</b> , 99, 1045-50		36
707	Dégénérescence maculaire liée à l'âge. État des lieux 2015. <b>2015</b> , 8, 118-135		0

706	Novel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability. <b>2015</b> , 185, 2534-49		18
705	Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom. <i>Eye</i> , <b>2015</b> , 29, 403-8	4.4	14
704	Clinical characteristics and outcomes after 5 years pro re nata treatment of neovascular age-related macular degeneration with ranibizumab. <i>Acta Ophthalmologica</i> , <b>2015</b> , 93, e511-2	3.7	5
703	Gene- and Cell-Based Treatment Strategies for the Eye. <b>2015</b> ,		1
702	ROCK-isoform-specific polarization of macrophages associated with age-related macular degeneration. <b>2015</b> , 10, 1173-86		116
701	Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab. <b>2015</b> , 59, 36-42		18
700	Antibody therapies and their challenges in the treatment of age-related macular degeneration. <b>2015</b> , 95, 158-72		42
699	Individualizing the intravitreal anti-VEGF dosing regimen for long-term management of neovascular AMD. <b>2015</b> , 46, 508-12		5
698	Increased Fundus Autofluorescence and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GAIN Study. <b>2015</b> , 160, 345-353.e5		42
697	Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study. <i>Ophthalmology</i> , <b>2015</b> , 122, 1837-45	7.3	152
696	Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. <b>2015</b> , 99, 220-6		320
695	Advances in pharmacotherapy for wet age-related macular degeneration. <b>2015</b> , 16, 1769-81		23
694	Stem cell based therapies for age-related macular degeneration: The promises and the challenges. <i>Progress in Retinal and Eye Research</i> , <b>2015</b> , 48, 1-39	20.5	133
693	Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. <b>2015</b> , 159, 915-24.e2		125
692	Long-Term Results of Full Macular Translocation for Choroidal Neovascularization in Age-Related Macular Degeneration. <i>Ophthalmology</i> , <b>2015</b> , 122, 1366-74	7.3	17
691	[Forms of age-related macular degeneration]. <b>2015</b> , 112, 373-85; quiz 386		0
690	[Anti-VEGF therapy for neovascular age-related macular degeneration -therapeutic strategies: statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of Ophthalmologists in Germany - November 2014]. <b>2015</b> , 112, 237-45		8
689	Long-term outcome of intravitreal pegaptanib sodium as maintenance therapy in Japanese patients with neovascular age-related macular degeneration. <b>2015</b> , 59, 173-8		5

688	Defining response to anti-VEGF therapies in neovascular AMD. <i>Eye</i> , <b>2015</b> , 29, 721-31	4.4	132
687	Emerging therapeutic options in age-related macular degeneration. <b>2015</b> , 53, 194-9		8
686	Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy. <i>BMC Ophthalmology</i> , <b>2015</b> , 15, 37	2.3	7
685	Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel. <i>Eye</i> , <b>2015</b> , 29 Suppl 1, S1-S11	4.4	16
684	[Statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of German Ophthalmologists: The anti-VEGF therapy in neovascular age-related macular degeneration: Therapeutic Strategies (November 2014)]. <b>2015</b> , 232, 202-10		6
683	Ranibizumab treatment for retinal angiomatous proliferation lesions: a case report with life-long expectancy (seven years) follow-up. <b>2015</b> , 232, 570-2		
682	Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. <b>2015</b> , 386, 2395-403		128
681	[Long-Term Outcome in Patients with Intravitreal Anti-VEGF Therapy for Exudative AMD]. <b>2015</b> , 232, 533-7		5
680	Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward. <b>2015</b> , 18, 397-432		26
679	Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study. <i>Ophthalmology</i> , <b>2015</b> , 122, 2303-10 <sup>73</sup>		70
678	Parainflammation, chronic inflammation, and age-related macular degeneration. <b>2015</b> , 98, 713-25		165
677	Response-based individualized medicine for neovascular age-related macular degeneration. <b>2015</b> , 10, 105-112		2
676	Peripapillary RNFL thickness in nonexudative versus chronically treated exudative age-related macular degeneration. <b>2015</b> , 50, 345-9		5
675	Reevaluating the definition of intraretinal microvascular abnormalities and neovascularization elsewhere in diabetic retinopathy using optical coherence tomography and fluorescein angiography. <b>2015</b> , 159, 101-10.e1		51
674	AAV2 delivery of Flt23k intraceptors inhibits murine choroidal neovascularization. <b>2015</b> , 23, 226-34		16
673	Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye. <b>2015</b> , 21, 43-51		80
672	Vision-threatening lesions developing with longer-term follow-up after treatment of neovascular age-related macular degeneration. <i>Ophthalmology</i> , <b>2015</b> , 122, 153-61	7.3	21
671	Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes. <b>2016</b> , 10, 313-9		11

670	The Intraocular Cytokine Profile and Therapeutic Response in Persistent Neovascular Age-Related Macular Degeneration. <b>2016</b> , 57, 4144-50		52
669	Intravitreal Anti-Vascular Endothelial Growth Factor for Retinal Pigment Epithelial Tear in Retinal Angiomatous Proliferation. <b>2016</b> , 57, 71		1
668	Beyond VEGF-The Weisenfeld Lecture. <b>2016</b> , 57, 6911-6918		36
667	Intravitreal Anti-Vascular Endothelial Growth Factor Therapy and Retinal Nerve Fiber Layer Loss in Eyes With Age-Related Macular Degeneration: A Meta-Analysis. <b>2016</b> , 57, 1798-806		30
666	Stemming the Tide of Age-Related Macular Degeneration: New Therapies for Old Retinas. <b>2016</b> , 57, ORSFb1-3	7	
665	Geographic Atrophy and Activity of Neovascularization in Retinal Angiomatous Proliferation. <b>2016</b> , 57, 1500-5		15
664	OCT Angiography-Based Detection and Quantification of the Neovascular Network in Exudative AMD. <b>2016</b> , 57, 6342-6348		25
663	Different Ipsi- and Contralateral Glial Responses to Anti-VEGF and Triamcinolone Intravitreal Injections in Rats. <b>2016</b> , 57, 3533-44		18
662	Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up. <b>2016</b> , 10, 1047-51		4
661	Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment. <b>2016</b> , 10, 2505-2513		3
660	C3a Increases VEGF and Decreases PEDF mRNA Levels in Human Retinal Pigment Epithelial Cells. <b>2016</b> , 2016, 6958752		15
659	Effects of Intravitreal Ranibizumab Injection on Chinese Patients with Wet Age-Related Macular Degeneration: 5-Year Follow-Up Results. <b>2016</b> , 2016, 6538192		1
658	Biomaterials for intraocular sustained drug delivery. <b>2016</b> , 131-147		
657	Fucoidan as a Potential Therapeutic for Major Blinding Diseases--A Hypothesis. <b>2016</b> , 14,		25
656	Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. <b>2016</b> , 10, 1857-67		111
655	AFLIBERCEPT FOR THE TREATMENT OF RETINAL PIGMENT EPITHELIAL DETACHMENTS. <i>Retina</i> , <b>2016</b> , 36, 492-8	3.6	18
654	INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY. <i>Retina</i> , <b>2016</b> , 36, 770-7	3.6	19
653	INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: 5-Year Results of The Pan-American Collaborative Retina Study Group. <i>Retina</i> , <b>2016</b> , 36, 859-67	3.6	39



652	Distal retinal ganglion cell axon transport loss and activation of p38 MAPK stress pathway following VEGF-A antagonism. <b>2016</b> , 7, e2212		18
651	Characterizing relationship between optical microangiography signals and capillary flow using microfluidic channels. <b>2016</b> , 7, 2709-28		34
650	SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT. <i>Retina</i> , <b>2016</b> , 36, 1126-31	3.6	32
649	Interleukin-17A neutralization alleviated ocular neovascularization by promoting M2 and mitigating M1 macrophage polarization. <b>2016</b> , 147, 414-28		35
648	Extended release anti-VEGF systems: a strategy whose time has come? Or already gone?. <b>2016</b> , 11, 167-169		
647	[Compliance of age related macular degeneration patients undergoing anti-VEGF therapy : Analysis and suggestions for improvement]. <b>2016</b> , 113, 925-932		11
646	Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. <b>2017</b> , 101, 353-359		73
645	UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92 976 intravitreal ranibizumab injections. <b>2016</b> , 100, 1617-1622		13
644	Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy. <b>2016</b> , 100, 1611-1616		5
643	Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. <b>2016</b> , 100, 1640-1645		30
642	Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. <b>2016</b> , 100, 1341-5		31
641	Sustained intraocular VEGF neutralization results in retinal neurodegeneration in the Ins2(Akita) diabetic mouse. <b>2015</b> , 5, 18316		41
640	Increased VEGF-A promotes multiple distinct aging diseases of the eye through shared pathomechanisms. <b>2016</b> , 8, 208-31		31
639	VISUALIZING RETINAL PIGMENT EPITHELIUM PHENOTYPES IN THE TRANSITION TO ATROPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2016</b> , 36 Suppl 1, S26-S39	3.6	43
638	Interferon-beta signaling in retinal mononuclear phagocytes attenuates pathological neovascularization. <b>2016</b> , 8, 670-8		53
637	Wide-field optical coherence tomography based microangiography for retinal imaging. <b>2016</b> , 6, 22017		89
636	METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2016</b> , 36, 1418-31	3.6	104
635	Age-related macular degeneration. <b>2016</b> , 77, C18-21		7

634	Burning fat fuels photoreceptors. <b>2016</b> , 22, 342-3		10
633	Patient iPSCs: a new discovery tool for Smith-Lemli-Opitz syndrome. <b>2016</b> , 22, 343-4		2
632	A sustained release formulation of novel quininib-hyaluronan microneedles inhibits angiogenesis and retinal vascular permeability in vivo. <b>2016</b> , 233, 198-207		22
631	Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. <i>Progress in Retinal and Eye Research</i> , <b>2016</b> , 53, 107-139	20.5	205
630	Neutralization of IL-23 depresses experimental ocular neovascularization. <b>2016</b> , 146, 242-251		12
629	Retinal Ganglion Cell Layer Change in Patients Treated With Anti-Vascular Endothelial Growth Factor for Neovascular Age-related Macular Degeneration. <b>2016</b> , 167, 10-7		44
628	Long-Term Outcomes of Anti-Vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy. <b>2016</b> , 32, 219-24		10
627	Pharmacology of the retinal pigment epithelium, the interface between retina and body system. <b>2016</b> , 787, 84-93		19
626	Manual of Retinal Diseases. <b>2016</b> ,		1
625	Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts. <b>2016</b> , 33, 715-26		9
624	Retinal Vascular Occlusions: Review of Clinical Trials. <b>2016</b> , 311-314		
623	Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , <b>2016</b> , 123, 1751-1761	7.3	389
622	Long-term Results of Intravitreal Anti-VEGF Injections in Wet AMD: A Meta-Analysis. <b>2016</b> , 233, 471-4		14
621	Anti-Angiogenic Therapy in Ophthalmology. <b>2016</b> ,		3
620	Anti-vascular Endothelial Growth Factor (VEGF) Treatment in Neovascular Age-Related Macular Degeneration: Outcomes and Outcome Predictors. <b>2016</b> , 31-65		
619	Method development to quantify Bv8 expression in circulating CD11b+ cells in patients with neovascular age-related macular degeneration (nvAMD) exhibiting Anti-VEGF refractoriness. <b>2016</b> , 148, 45-51		4
618	UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: Incidence of Blindness and Sight Impairment in Ranibizumab-Treated Patients. <i>Ophthalmology</i> , <b>2016</b> , 123, 2386-2392	7.3	21
617	Tenascin-C secreted by transdifferentiated retinal pigment epithelial cells promotes choroidal neovascularization via integrin $\alpha$ . <b>2016</b> , 96, 1178-1188		15

616	[Atrophy of the macula in the context of its wet, age-related degeneration : An inescapable consequence of anti-VEGF therapy?]. <b>2016</b> , 113, 1036-1045		9
615	On the Use of Photodynamic Therapy, as Monotherapy or in Combination, in the Treatment of Polypoidal Choroidal Vasculopathy: An Update. <b>2016</b> , 421-435		1
614	A Revised Hemodynamic Theory of Age-Related Macular Degeneration. <b>2016</b> , 22, 656-670		34
613	Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. <i>Eye</i> , <b>2016</b> , 30, 1531-1541	4.4	9
612	Real world evidence of use of anti-VEGF therapy in Denmark. <b>2016</b> , 32, 1943-1950		19
611	[Ranibizumab and exudative age-related macular degeneration: 5-year multicentric functional and anatomical results in real-life practice]. <b>2016</b> , 39, 668-674		10
610	Role of Omega-3 Fatty Acids for Eye Health. <b>2016</b> , 251-261		
609	Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , <b>2016</b> , 94, e757-e764	3.7	71
608	Licence to save: a UK survey of anti-VEGF use for the eye in 2015. <i>Eye</i> , <b>2016</b> , 30, 1404-1406	4.4	12
607	Big Data and Uveitis. <i>Ophthalmology</i> , <b>2016</b> , 123, 2273-2275	7.3	14
606	Retinal pigment epithelial atrophy over polypoidal choroidal vasculopathy lesions during ranibizumab monotherapy. <i>BMC Ophthalmology</i> , <b>2016</b> , 16, 55	2.3	5
605	GEOGRAPHIC ATROPHY: Semantic Considerations and Literature Review. <i>Retina</i> , <b>2016</b> , 36, 2250-2264	3.6	38
604	TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT FOR RETINAL ANGIOMATOUS PROLIFERATION. <i>Retina</i> , <b>2016</b> , 36, 2282-2289	3.6	26
603	Stereotactic radiotherapy in neovascular age-related macular degeneration: Real-life efficacy and morphological evaluation of the outer retina-choroid complex. <b>2016</b> , 95, e5729		13
602	Association of Anti-VEGF Injections with Progression of Geographic Atrophy. <b>2016</b> , 8, 31-2		18
601	The concept of virtual clinics in monitoring patients with age-related macular degeneration. <i>Acta Ophthalmologica</i> , <b>2016</b> , 94, e353-5	3.7	21
600	Prognostic implications of imaging in atrophic macular degeneration and its use in clinical practice and clinical trial design. <b>2016</b> , 44, 410-21		1
599	Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration. <b>2016</b> , 169, 95-103		23

598	Targeting Platelet-Derived Growth Factor Receptor (α) Scaffold Formation Inhibits Choroidal Neovascularization. <b>2016</b> , 186, 1890-9		23
597	[Long-term results in neovascular age-related macular degeneration : Changes in visual acuity and geographic atrophy during long-standing anti-VEGF therapy]. <b>2016</b> , 113, 668-74		5
596	Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration. <b>2016</b> , 168, 1-12		73
595	Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration. <b>2016</b> , 145, 248-257		14
594	Targeting VEGF in eye neovascularization: What's new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development. <b>2016</b> , 103, 253-69		106
593	Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study). <i>Ophthalmology</i> , <b>2016</b> , 123, 1269-77	7.3	53
592	Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis. <b>2016</b> , 291, 7242-55		28
591	Economic and Quality of Life Benefits of Anti-VEGF Therapy. <b>2016</b> , 13, 2877-80		14
590	Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , <b>2016</b> , 235, 42-8	3.7	19
589	Malondialdehyde induces autophagy dysfunction and VEGF secretion in the retinal pigment epithelium in age-related macular degeneration. <b>2016</b> , 94, 121-34		35
588	NRP1 function and targeting in neurovascular development and eye disease. <i>Progress in Retinal and Eye Research</i> , <b>2016</b> , 52, 64-83	20.5	34
587	Treatment for neovascular age related macular degeneration: The state of the art. <b>2016</b> , 787, 78-83		17
586	Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular Degeneration After Ranibizumab Treatment. <b>2016</b> , 161, 94-103.e1		32
585	The design and implementation of a study to investigate the effectiveness of community vs hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease. <i>Eye</i> , <b>2016</b> , 30, 68-78	4.4	3
584	VEGF-A and the NLRP3 Inflammasome in Age-Related Macular Degeneration. <b>2016</b> , 854, 79-85		13
583	Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK. <b>2016</b> , 100, 240-5		8
582	A 24-Month Evaluation of Aflibercept for Wet Age-Related Macular Degeneration in Patients Previously Receiving Ranibizumab or Bevacizumab. <i>Ophthalmology Retina</i> , <b>2017</b> , 1, 111-117	3.8	1
581	Risk of Posterior Capsule Rupture During Cataract Surgery in Eyes With Previous Intravitreal Injections. <b>2017</b> , 177, 77-80		13

580	MicroRNA-processing Enzymes Are Essential for Survival and Function of Mature Retinal Pigmented Epithelial Cells in Mice. <b>2017</b> , 292, 3366-3378		20
579	Fundus autofluorescence imaging: systematic review of test accuracy for the diagnosis and monitoring of retinal conditions. <i>Eye</i> , <b>2017</b> , 31, 995-1007	4.4	10
578	Targeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment. <b>2017</b> , 25, 1606-1615		8
577	The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited. <b>2017</b> , 3, 5		9
576	Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2017</b> , 255, 963-972	3.8	34
575	Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injections. <b>2017</b> , 36, 343-346		19
574	Sema3f Protects Against Subretinal Neovascularization In Vivo. <b>2017</b> , 18, 281-287		15
573	Special Commentary: Early Clinical Development of Cell Replacement Therapy: Considerations for the National Eye Institute Audacious Goals Initiative. <i>Ophthalmology</i> , <b>2017</b> , 124, 926-934	7.3	8
572	RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2017</b> , 37, 2035-2046	3.6	9
571	Choroidal thickness and visual prognosis in type 1 lesion due to neovascular age-related macular degeneration. <b>2017</b> , 27, 196-200		4
570	Advances in Vision Research, Volume I. <b>2017</b> ,		
569	ROLE OF ADDITIONAL DEXAMETHASONE FOR THE MANAGEMENT OF PERSISTENT OR RECURRENT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDER RANIBIZUMAB TREATMENT. <i>Retina</i> , <b>2017</b> , 37, 962-970	3.6	15
568	Autologous Bone Marrow-Derived Cell Therapies for Retinal Disease. <b>2017</b> , 79-94		
567	Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial. <b>2017</b> , 180, 142-150		51
566	Decreased Visual Function Scores on a Low Luminance Questionnaire Is Associated with Impaired Dark Adaptation. <i>Ophthalmology</i> , <b>2017</b> , 124, 1332-1339	7.3	19
565	Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2017</b> , 255, 1259-1273	3.8	71
564	Vitamin D receptor agonists regulate ocular developmental angiogenesis and modulate expression of dre-miR-21 and VEGF. <b>2017</b> , 174, 2636-2651		29
563	LONG-TERM OUTCOMES AND INCIDENCE OF RECURRENCE OF NEOVASCULARIZATION IN TREATED EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2017</b> , 37, 951-961	3.6	14

562	On phagocytes and macular degeneration. <i>Progress in Retinal and Eye Research</i> , <b>2017</b> , 61, 98-128	20.5	80
561	Economic Evaluation of a Home-Based Age-Related Macular Degeneration Monitoring System. <b>2017</b> , 135, 452-459		21
560	[Individualized management of patients with exudative AMD, IOI protocol: Injection-observational-individualization]. <b>2017</b> , 40, 169-176		2
559	One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for Exudative Age-Related Macular Degeneration. <i>Ophthalmologica</i> , <b>2017</b> , 237, 139-144	3.7	19
558	Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. <b>2017</b> , 376, 1038-1046		785
557	Autophagy and KRT8/keratin 8 protect degeneration of retinal pigment epithelium under oxidative stress. <b>2017</b> , 13, 248-263		40
556	Polysialic acid blocks mononuclear phagocyte reactivity, inhibits complement activation, and protects from vascular damage in the retina. <b>2017</b> , 9, 154-166		43
555	Proteolytic Degradation and Inflammation Play Critical Roles in Polypoidal Choroidal Vasculopathy. <b>2017</b> , 187, 2841-2857		18
554	Comparison of Strategies of Treatment with Ranibizumab in Newly-Diagnosed Cases of Neovascular Age-Related Macular Degeneration. <b>2017</b> , 33, 773-778		7
553	Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections. <i>Ophthalmologica</i> , <b>2017</b> , 238, 217-225	3.7	7
552	High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases. <b>2017</b> , 266, 301-309		23
551	Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register. <i>Acta Ophthalmologica</i> , <b>2017</b> , 95, 787-795	3.7	16
550	Cell Therapy for Ophthalmic Diseases. <b>2017</b> , 249-279		1
549	A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration. <b>2017</b> , 7, 9196		22
548	An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , <b>2017</b> , 95, 796-802	3.7	48
547	Changes in Peripapillary Nerve Fiber Layer Thickness after Adjuvant Stereotactic Radiotherapy in Patients with Neovascular Age-Related Macular Degeneration. <i>Current Eye Research</i> , <b>2017</b> , 42, 1698-1706 <sup>2,9</sup>		1
546	2016 Glenn A. Fry Award Lecture: Mechanisms and Potential Treatments of Early Age-Related Macular Degeneration. <b>2017</b> , 94, 939-945		1
545	Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology Retina</i> , <b>2017</b> , 1, 474-485	3.8	42

544	Age-related macular degeneration: is polypoidal choroidal vasculopathy recognized and treated?. <b>2017</b> , 52, 475-479		3
543	A Proinflammatory Function of Toll-Like Receptor 2 in the Retinal Pigment Epithelium as a Novel Target for Reducing Choroidal Neovascularization in Age-Related Macular Degeneration. <b>2017</b> , 187, 2208-2221 <sup>19</sup>		
542	ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2017</b> , 255, 2091-2098	3.8	8
541	A genome-wide association study identified a novel genetic loci STON1-GTF2A1L/LHCGR/FSHR for bilaterality of neovascular age-related macular degeneration. <b>2017</b> , 7, 7173		6
540	RISK FACTORS AND CLINICAL SIGNIFICANCE OF PRECHOROIDAL CLEFT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2017</b> , 37, 2047-2055	3.6	8
539	Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration. <b>2017</b> , 96, e6422		6
538	Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development. <b>2017</b> , 26, 1103-1114		15
537	Pluripotent stem cells and their utility in treating photoreceptor degenerations. <b>2017</b> , 231, 191-223		11
536	Hot Topics in Pharmacotherapy for Neovascular Age-Related Macular Degeneration. <b>2017</b> , 23, 535-541		5
535	Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2017</b> , 255, 1891-1897	3.8	40
534	Identification of different macrophage subpopulations with distinct activities in a mouse model of oxygen-induced retinopathy. <b>2017</b> , 40, 281-292		27
533	Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , <b>2017</b> , 124, 97-104	7.3	113
532	Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration. <b>2017</b> , 61, 74-83		12
531	Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. <i>Eye</i> , <b>2017</b> , 31, 1-9	4.4	62
530	New Treatment Modalities for Neovascular Age-Related Macular Degeneration. <b>2017</b> , 6, 514-519		16
529	Anti-VEGF Therapy for Neovascular AMD and Polypoidal Choroidal Vasculopathy. <b>2017</b> , 6, 527-534		20
528	Recent developments in age-related macular degeneration: a review. <b>2017</b> , 12, 1313-1330		168
527	Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning. <b>2017</b> , 11, 809-816		9

526	Effects of bevacizumab on endoplasmic reticulum stress in hypoxic retinal pigment epithelial cells. <i>PLoS ONE</i> , <b>2017</b> , 12, e0179048	3.7	6
525	Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab. <i>BMC Ophthalmology</i> , <b>2017</b> , 17, 147	2.3	8
524	Investigation of time to first presentation and extrahospital factors in the treatment of neovascular age-related macular degeneration: a retrospective cross-sectional study. <i>BMJ Open</i> , <b>2017</b> , 7, e017771	3	10
523	The Implantable Miniature Telescope and Quality of Life Improvements in Patients with End-Stage Age-Related Macular Degeneration. <b>2017</b> , 07,		0
522	Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience. <b>2017</b> , 31, 424-430		8
521	New molecular targets for the treatment of neovascular age-related macular degeneration. <b>2017</b> , 1,		
520	Neovascular (Wet) Age-Related Macular Degeneration. <b>2017</b> , 89-116		0
519	CD11b and CD200 on Circulating Monocytes Differentiate Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy. <b>2017</b> , 58, 5242-5250		16
518	MicroRNA-370 suppresses the retinal capillary endothelial cell growth by targeting KDR gene. <b>2017</b> , 118, 202-207		7
517	Galectin-3 Inhibition by a Small-Molecule Inhibitor Reduces Both Pathological Corneal Neovascularization and Fibrosis. <b>2017</b> , 58, 9-20		39
516	Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration. <b>2017</b> , 58, 6038-6045		9
515	Advances in Age-related Macular Degeneration Understanding and Therapy. <b>2017</b> , 10, 119-130		39
514	Autophagy activated by SIRT6 regulates A $\beta$ induced inflammatory response in RPEs. <b>2018</b> , 496, 1148-1154		12
513	The fate of eyes with wet AMD beyond four years of anti-VEGF therapy. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2018</b> , 256, 823-831	3.8	16
512	Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration. <b>2018</b> , 63, 638-645		29
511	Human aging and disease: Lessons from age-related macular degeneration. <b>2018</b> , 115, 2866-2872		38
510	Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium. <b>2018</b> , 171, 1-11		10
509	Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , <b>2018</b> , 125, 878-886	7.3	63



508	Anti-vascular endothelial growth factors treatment of wet age-related macular degeneration: from neurophysiology to cost-effectiveness. <i>Acta Ophthalmologica</i> , <b>2018</b> , 96 Suppl A109, 1-46	3.7	2
507	Inhibition of integrin $\alpha_5$ ameliorates VEGF-induced retinal neovascularization and leakage by suppressing NLRP3 inflammasome signaling in a mouse model. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2018</b> , 256, 951-961	3.8	14
506	Choroidal pericytes promote subretinal fibrosis after experimental photocoagulation. <b>2018</b> , 11,		12
505	Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , <b>2018</b> , 125, 1037-1046	7.3	37
504	Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol. <i>Ophthalmology</i> , <b>2018</b> , 125, 1047-1053	7.3	39
503	Treat-and-Extend Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration: Efficacy and Macular Atrophy Development. <i>Ophthalmology Retina</i> , <b>2018</b> , 2, 462-468	3.8	15
502	Long-Term Assessment of Macular Atrophy in Patients with Age-Related Macular Degeneration Receiving Anti-Vascular Endothelial Growth Factor. <i>Ophthalmology Retina</i> , <b>2018</b> , 2, 550-557	3.8	7
501	AAV-mediated gene delivery of the calreticulin anti-angiogenic domain inhibits ocular neovascularization. <b>2018</b> , 21, 95-109		8
500	A 5-year multicenter prospective cohort study on the long-term visual prognosis and predictive factors for visual outcome in Japanese patients with age-related macular degeneration: the AMD2000 study. <b>2018</b> , 62, 137-143		2
499	Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. <i>Progress in Retinal and Eye Research</i> , <b>2018</b> , 65, 127-146	20.5	128
498	Combined VEGF/PDGF inhibition using axitinib induces $\alpha$ MA expression and a pro-fibrotic phenotype in human pericytes. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2018</b> , 256, 1141-1149	3.8	9
497	INTRAVITREAL AFLIBERCEPT INJECTION FOR CHOROIDDAL NEOVASCULARIZATION DUE TO PRESUMED OCULAR HISTOPLASMOSIS SYNDROME: The HANDLE Study. <i>Retina</i> , <b>2018</b> , 38, 755-763	3.6	4
496	WRINKLED VASCULARIZED RETINAL PIGMENT EPITHELIUM DETACHMENT PROGNOSIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. <i>Retina</i> , <b>2018</b> , 38, 1100-1109	3.6	7
495	Aquaporins: Novel Targets for Age-Related Ocular Disorders. <b>2018</b> , 34, 177-187		7
494	TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN EVERYDAY PRACTICE: Identification of Health Care Constraints in Germany-The PONS Study. <i>Retina</i> , <b>2018</b> , 38, 1134-1144	3.6	9
493	OUTCOMES OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR THREE OR MORE YEARS: A Review of Current Outcomes. <i>Retina</i> , <b>2018</b> , 38, 1500-1508	3.6	20
492	PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis. <i>Retina</i> , <b>2018</b> , 38, 1276-1288	3.6	32
491	Reply to: 'Comment on: 'One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration'. <i>Eye</i> , <b>2018</b> , 32, 479-481	4.4	

490	Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data. <b>2018</b> , 102, 465-472		6
489	INTRAVITREAL INJECTION OF AFLIBERCEPT IN PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY: A 3-YEAR FOLLOW-UP. <i>Retina</i> , <b>2018</b> , 38, 2001-2009	3.6	15
488	Clinical and social characteristics associated with reduced visual acuity at presentation in Australian patients with neovascular age-related macular degeneration: a prospective study from a long-term observational data set. The Fight Retinal Blindness! Project. <b>2018</b> , 46, 266-274		3
487	Recurrence Rate of Choroidal Neovascularization in Neovascular Age-Related Macular Degeneration Managed with a Treat-Extend-Stop Protocol. <i>Ophthalmology Retina</i> , <b>2018</b> , 2, 225-230	3.8	29
486	Potential selection bias in candidates for stereotactic radiotherapy for neovascular AMD. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2018</b> , 256, 105-111	3.8	2
485	Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration. <i>Acta Ophthalmologica</i> , <b>2018</b> , 96, e393-e398	3.7	27
484	Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials. <i>Ophthalmology Retina</i> , <b>2018</b> , 2, 525-530	3.8	28
483	Evolving multidimensional pharmacological approaches to CNV therapy in AMD. <i>Current Eye Research</i> , <b>2018</b> , 43, 147-154	2.9	6
482	Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration. <i>Ophthalmology</i> , <b>2018</b> , 125, 66-74	7.3	49
481	Intravitreal Anti-vascular Endothelial Growth Factor Injections to Treat Neovascular Age-related Macular Degeneration: Long-term Treatment Outcomes. <b>2018</b> , 59, 1142		2
480	Long-term Treatment Outcome of Intravitreal Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy. <b>2018</b> , 59, 238		2
479	Reply. <i>Retina</i> , <b>2018</b> , 38, e85-e86	3.6	0
478	Reply. <i>Retina</i> , <b>2018</b> , 38, e84-e85	3.6	
477	Long term outcome after anti-VEGF treatment—what do we know about the impact of morphological parameters?. <b>2018</b> , 3, 57-57		
476	Age related macular degeneration: from evidence based-care to experimental models. <b>2018</b> , 3, 1-1		4
475	Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration. <b>2018</b> , 11, 645-649		2
474	Quantitative proteomic analysis of aqueous humor from patients with drusen and reticular pseudodrusen in age-related macular degeneration. <i>BMC Ophthalmology</i> , <b>2018</b> , 18, 289	2.3	16
473	Myofibroblasts in macular fibrosis secondary to neovascular age-related macular degeneration - the potential sources and molecular cues for their recruitment and activation. <b>2018</b> , 38, 283-291		22

472	Prechoroidal Cleft in Type 3 Neovascularization: Incidence, Timing, and Its Association with Visual Outcome. <b>2018</b> , 2018, 2578349		6
471	Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration Smoking and Anti-VEGF Therapy in nAMD. <b>2018</b> , 2018, 2353428		2
470	An update on inflammatory choroidal neovascularization: epidemiology, multimodal imaging, and management. <b>2018</b> , 8, 13		53
469	Age-related macular degeneration. <b>2018</b> , 392, 1147-1159		455
468	Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-effectiveness Analysis. <b>2018</b> , 1-9		1
467	Systemic immunosuppression and risk of age-related macular degeneration. <i>PLoS ONE</i> , <b>2018</b> , 13, e0203492	3-7	4
466	Human embryonic stem cell-derived retinal pigment epithelium transplants as a potential treatment for wet age-related macular degeneration. <b>2018</b> , 4, 50		36
465	The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea. <i>PLoS ONE</i> , <b>2018</b> , 13, e0206690	3-7	7
464	Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment. <b>2018</b> , 12, 1877-1885		16
463	Reply. <i>Ophthalmology</i> , <b>2018</b> , 125, e84-e85		7-3
462	Loss to Follow-up Among Patients With Neovascular Age-Related Macular Degeneration Who Received Intravitreal Anti-Vascular Endothelial Growth Factor Injections. <b>2018</b> , 136, 1251-1259		33
461	Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial. <b>2018</b> , 12, 587-591		2
460	Noninfectious Inflammatory Response following Intravitreal Bevacizumab Injections: Description of a Cluster of Cases in Two Centers and a Review of the Literature. <i>Ophthalmologica</i> , <b>2018</b> , 240, 163-166	3-7	6
459	Low incidence of choroidal neovascularization following subthreshold diode micropulse laser (SDM) in high-risk AMD. <i>PLoS ONE</i> , <b>2018</b> , 13, e0202097	3-7	12
458	Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells. <b>2018</b> , 32, 328-338		
457	Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance. <b>2018</b> , 12, 593-600		7
456	Safety and Feasibility of a Novel Sparse Optical Coherence Tomography Device for Patient-Delivered Retina Home Monitoring. <b>2018</b> , 7, 8		26
455	Would intravitreal bevacizumab injection increase risk of cerebral infarction?. <b>2018</b> , 25, 1177-1181		

454	In vivo anti-vascular endothelial growth factor treatment induces corneal endothelium apoptosis in rabbits through changes in p75NTR-proNGF pathway. <b>2018</b> , 233, 8874-8883		4
453	Quantitative biometry of zebrafish retinal vasculature using optical coherence tomographic angiography. <b>2018</b> , 9, 1244-1255		8
452	Multimodal Imaging Patterns for Development of Central Atrophy Secondary to Age-Related Macular Degeneration. <b>2018</b> , 59, AMD1-AMD11		14
451	Morphological Predictive Features on Spectral-Domain Optical Coherence Tomography for Visual Outcomes in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab. <b>2018</b> , 2018, 7438083		2
450	Prediction of Individual Disease Conversion in Early AMD Using Artificial Intelligence. <b>2018</b> , 59, 3199-3208		94
449	Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis. <b>2018</b> , 24, 608-616		15
448	C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration. <b>2018</b> , 9, 808		25
447	Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy. <b>2018</b> , 25, 1537-1545		11
446	New Therapies of Neovascular AMD beyond Anti-VEGF Injections. <b>2018</b> , 2,		7
445	Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting. <b>2018</b> , 7, 361-368		29
444	Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab. <i>BMC Ophthalmology</i> , <b>2018</b> , 18, 20	2.3	1
443	Endophthalmitis Following Intravitreal Injection. <b>2018</b> , 6, 145-151		6
442	Past and prognosis of anti-VEGF therapy for wet age-related macular degeneration-the future has begun. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2018</b> , 256, 1553-1555	3.8	2
441	Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study. <b>2018</b> , 12, 1137-1147		5
440	Bevacizumab Promotes T-Cell-Mediated Collagen Deposition in the Mouse Model of Conjunctival Scarring. <b>2018</b> , 59, 1682-1692		2
439	Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. <b>2018</b> , 24, S3-S15		59
438	Alk1 (Activin Receptor-Like Kinase 1) and Vascular Hyperpermeability in Diabetic Retinopathy. <b>2018</b> , 38, 1673-1675		1
437	Liquid Biopsy of Vitreous Reveals an Abundant Vesicle Population Consistent With the Size and Morphology of Exosomes. <b>2018</b> , 7, 6		36

436	New Therapies of Neovascular AMD-Beyond Anti-VEGFs. <b>2018</b> , 2,		2
435	Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy. <b>2019</b> , 103, 617-622		12
434	Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study. <b>2019</b> , 103, 844-848		13
433	Comparison of long-term clinical evolution in highly myopic eyes with vertical oval-shaped dome with or without untreated serous retinal detachment. <b>2019</b> , 103, 385-389		8
432	Accuracy of ultra-wide-field fundus ophthalmoscopy-assisted deep learning, a machine-learning technology, for detecting age-related macular degeneration. <i>International Ophthalmology</i> , <b>2019</b> , 39, 1269-1275	2.2	38
431	Optical Coherence Tomography-Based Deep-Learning Models for Classifying Normal and Age-Related Macular Degeneration and Exudative and Non-Exudative Age-Related Macular Degeneration Changes. <b>2019</b> , 8, 527-539		40
430	Long-Term Management of Neovascular Age-Related Macular Degeneration: To 'Suspend or Not to Suspend?. <i>Ophthalmology Retina</i> , <b>2019</b> , 3, 621-622	3.8	3
429	Optical coherence tomography angiography characteristics of choroidal neovascularization requiring varied dosing frequencies in treat-and-extend management: An analysis of the AVATAR study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0218889	3.7	9
428	Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months. <i>Ophthalmology Retina</i> , <b>2019</b> , 3, 623-628	3.8	14
427	Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration. <b>2019</b> , 13, 1323-1329		27
426	Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration. <b>2019</b> , 13, 1289-1295		0
425	A novel dendrimer-based complex co-modified with cyclic RGD hexapeptide and penetratin for noninvasive targeting and penetration of the ocular posterior segment. <b>2019</b> , 26, 989-1001		17
424	[Systemic biological treatment in ophthalmology]. <b>2019</b> , 160, 1744-1750		
423	Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. <b>2019</b> , 3, CD005139		67
422	Intraocular VEGF deprivation induces degeneration and fibrogenic response in retina. <b>2019</b> , 33, 13920-13934		3
421	Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease. <b>2019</b> , 17, 819-828		17
420	Novel method of treating macular degeneration: a patent evaluation (WO2018/107005). <b>2019</b> , 29, 749-752		3
419	Hyaluronic Acid-Antibody Fragment Bioconjugates for Extended Ocular Pharmacokinetics. <b>2019</b> , 30, 2782-2789		9

418	Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , <b>2019</b> , 126, 743-751	7.3	14
417	Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. <b>2019</b> , 137, 372-379		59
416	EFFECT OF SERIAL ANTERIOR CHAMBER PARACENTESIS ON SUSTAINED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS RECEIVING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. <i>Retina</i> , <b>2019</b> , 39, 1959-1964	3.6	4
415	Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2019</b> , 257, 1411-1418	3.8	10
414	Statins and Age-Related Macular Degeneration: Implications for Dietary Intake. <b>2019</b> , 569-583		
413	Recent advances in intraocular sustained-release drug delivery devices. <b>2019</b> , 24, 1694-1700		27
412	Looking ahead in retinal disease management:. <b>2019</b> , 5, 22		6
411	Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration. <b>2019</b> , 19, 735-751		13
410	Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets. <b>2019</b> , 146, 104277		2
409	Effects of Fucoidans from Five Different Brown Algae on Oxidative Stress and VEGF Interference in Ocular Cells. <b>2019</b> , 17,		21
408	Long-term therapeutic effect in nonhuman primate eye from a single injection of anti-VEGF controlled release hydrogel. <b>2019</b> , 4, e10128		8
407	Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema. <b>2019</b> , 103, 1356-1360		15
406	Current perspectives on established and novel therapies for pathological neovascularization in retinal disease. <b>2019</b> , 164, 321-325		17
405	Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. <b>2019</b> , 60, 1088-1095		19
404	Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a "Treat-and-Extend" Regimen. <i>Ophthalmology Retina</i> , <b>2019</b> , 3, 393-399	3.8	32
403	Three-Year Follow-Up of Phase 1 and 2a rAAV.sFLT-1 Subretinal Gene Therapy Trials for Exudative Age-Related Macular Degeneration. <b>2019</b> , 204, 113-123		29
402	Fundus autofluorescence and retinal sensitivity in fellow eyes of age-related macular degeneration in Japan. <i>PLoS ONE</i> , <b>2019</b> , 14, e0213161	3.7	3
401	Intravitreal Ets1 siRNA alleviates choroidal neovascularization in a mouse model of age-related macular degeneration. <b>2019</b> , 376, 341-351		5

400	Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy. <b>2019</b> , 9, 3620		17
399	Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy. <b>2019</b> , 16, 38-50		29
398	Intravitreal conbercept injection for neovascular age-related macular degeneration. <b>2019</b> , 12, 252-257		6
397	Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part I: A Review of Disease Characterization and Morphological Associations. <b>2019</b> , 8, 235-249		9
396	Other Therapies in CSCR. <b>2019</b> , 305-316		
395	Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up. <i>Current Eye Research</i> , <b>2019</b> , 44, 908-913		6
394	Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. <i>Eye</i> , <b>2019</b> , 33, 1-21	4.4	25
393	Targeting P2X7 receptors as a means for treating retinal disease. <b>2019</b> , 24, 1598-1605		13
392	Mesopic and Dark-Adapted Two-Color Fundus-Controlled Perimetry in Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. <b>2019</b> , 8, 7		17
391	Device design methodology and formulation of a protein therapeutic for sustained release intraocular delivery. <b>2019</b> , 4, 152-163		6
390	The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. <b>2019</b> , 64, 707-719		18
389	Reply. <i>Ophthalmology</i> , <b>2019</b> , 126, e19-e20		73
388	Is Retinal Metabolic Dysfunction at the Center of the Pathogenesis of Age-related Macular Degeneration?. <b>2019</b> , 20,		39
387	Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. <b>2019</b> , 4, e000398		38
386	Treat-and-extend regimens with anti-vascular endothelial growth factor agents in age-related macular degeneration. <b>2019</b> , 14, 287-307		1
385	Microvascular contributions to age-related macular degeneration (AMD): from mechanisms of choriocapillaris aging to novel interventions. <b>2019</b> , 41, 813-845		29
384	Choroidal Neovascularization: Mechanisms of Endothelial Dysfunction. <b>2019</b> , 10, 1363		21
383	Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8). <b>2019</b> , 13, 2461-2467		5

382	Upcoming Therapies for Age-related Macular Degeneration. <b>2019</b> , 59, 155-171		
381	A case report detailing use of a new intraocular lens with advanced technology, designed specifically for patients with center-involving macular disorders. <b>2019</b> , 98, e16583		2
380	Following the Status of Visual Cortex Over Time in Patients With Macular Degeneration Reveals Atrophy of Visually Deprived Brain Regions. <b>2019</b> , 60, 5045-5051		9
379	Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen. <b>2019</b> , 103, 900-905		11
378	Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration: A Report by the American Academy of Ophthalmology. <i>Ophthalmology</i> , <b>2019</b> , 126, 55-63	7.3	66
377	Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence. <i>Ophthalmology Retina</i> , <b>2019</b> , 3, 8-15.e1 <sup>3.8</sup>		7
376	Retinal imaging including optical coherence tomography angiography for detecting active choroidal neovascularization in pseudoxanthoma elasticum. <b>2019</b> , 47, 240-249		8
375	Transplantation of photoreceptors into the degenerative retina: Current state and future perspectives. <i>Progress in Retinal and Eye Research</i> , <b>2019</b> , 69, 1-37	20.5	74
374	The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders. <b>2019</b> , 180, 43-52		16
373	Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , <b>2019</b> , 126, 252-260	7.3	83
372	Trainee-led versus specialist-led management of neovascular age-related macular degeneration: a registry-based study. <b>2019</b> , 103, 1158-1162		1
371	Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , <b>2019</b> , 126, 64-74	7.3	15
370	EXIT STRATEGY IN A TREAT-AND-EXTEND REGIMEN FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2019</b> , 39, 27-33	3.6	19
369	RETINAL PIGMENT EPITHELIUM-CHOROID GRAFT WITH A PERIPHERAL RETINOTOMY FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Long-Term Outcome. <i>Retina</i> , <b>2019</b> , 39, 288-295	3.6	6
368	OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2019</b> , 39, 303-313	3.6	8
367	MACULAR ATROPHY FINDINGS BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY COMPARED WITH FUNDUS AUTOFLUORESCENCE IN TREATED EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2019</b> , 39, 296-302	3.6	6
366	MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen. <i>Retina</i> , <b>2019</b> , 39, 906-917	3.6	18
365	Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study). <i>Ophthalmology</i> , <b>2020</b> , 127, 198-210	7.3	14



364	Innate immune response in retinal homeostasis and inflammatory disorders. <i>Progress in Retinal and Eye Research</i> , <b>2020</b> , 74, 100778	20.5	29
363	Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions. <b>2020</b> , 210, 116-124		31
362	Updates on Myopia. <b>2020</b> ,		4
361	SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States. <i>Ophthalmology Retina</i> , <b>2020</b> , 4, 122-133	3.8	15
360	Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , <b>2020</b> , 98, 132-138	3.7	14
359	Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. <i>Ophthalmology</i> , <b>2020</b> , 127, 186-195	7.3	101
358	Long-Term Incidence and Growth of Chorioretinal Atrophy in Patients with Polypoidal Choroidal Vasculopathy. <i>Ophthalmologica</i> , <b>2020</b> , 243, 136-144	3.7	3
357	Current Concepts in Ophthalmology. <b>2020</b> ,		
356	Optometry Australia's chairside reference for the diagnosis and management of age-related macular degeneration. <b>2020</b> , 103, 254-264		7
355	VEGF-Trap is a potent modulator of vasoregenerative responses and protects dopaminergic amacrine network integrity in degenerative ischemic neovascular retinopathy. <b>2020</b> , 153, 390-412		5
354	A Review of Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part II. <b>2020</b> , 9, 35-75		4
353	Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial. <b>2020</b> , 138, 244-250		21
352	Age-Related Macular Degeneration Preferred Practice Pattern <sup>®</sup> . <i>Ophthalmology</i> , <b>2020</b> , 127, P1-P65	7.3	76
351	Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology Retina</i> , <b>2020</b> , 4, 250-263	3.8	18
350	Undertreatment of Neovascular Age-Related Macular Degeneration after 10 Years of Anti-Vascular Endothelial Growth Factor Therapy in the Real World: The Need for A Change of Mindset. <i>Ophthalmologica</i> , <b>2020</b> , 243, 1-8	3.7	27
349	Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19. <i>Ophthalmology Retina</i> , <b>2020</b> , 4, 3-12	3.8	8
348	OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Identification of Choroidal Neovascularization Activity by Location and Quantification of Abnormal Fluid Under Anti-Vascular Endothelial Growth Factor Therapy. <i>Retina</i> , <b>2020</b> , 40, 881-890	3.6	4
347	EVALUATION OF SURGICAL FACTORS AFFECTING VITREOUS HEMORRHAGE FOLLOWING PORT DELIVERY SYSTEM WITH RANIBIZUMAB IMPLANT INSERTION IN A MINIPIG MODEL. <i>Retina</i> , <b>2020</b> , 40, 1520-1528	3.6	13

346	TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS. <i>Retina</i> , <b>2020</b> , 40, 1665-1672	3.6	10
345	Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project. <b>2020</b> , 104, 1064-1069		3
344	Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration. <b>2020</b> , 48, 300060520931618		0
343	Management Strategies and Visual Results for the Treatment of Neovascular Age-Related Macular Degeneration. <b>2020</b> ,		0
342	Agreement of Spectral-Domain OCT with Fluorescein Leakage in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study. <i>Ophthalmology Retina</i> , <b>2020</b> , 4, 1054-1058	3.8	3
341	Differences in Uptake and Intracellular Fate between Bevacizumab and Aflibercept after Repetitive Long-Term Treatment in the Retinal Pigment Epithelium. <b>2021</b> , 64, 369-388		3
340	Ten-year survival trends of neovascular age-related macular degeneration at first presentation. <b>2021</b> , 105, 1688-1695		5
339	Long-Term Follow-up of Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections. <i>Ophthalmology Retina</i> , <b>2020</b> , 4, 1047-1053	3.8	4
338	Combination of apolipoprotein-A-I/apolipoprotein-A-I binding protein and anti-VEGF treatment overcomes anti-VEGF resistance in choroidal neovascularization in mice. <i>Communications Biology</i> , <b>2020</b> , 3, 386	6.7	7
337	HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	43
336	Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration. <i>BMC Ophthalmology</i> , <b>2020</b> , 20, 276	2.3	5
335	Plasma level of lipocalin 2 is increased in neovascular age-related macular degeneration patients, particularly those with macular fibrosis. <b>2020</b> , 17, 35		3
334	IQGAP1 causes choroidal neovascularization by sustaining VEGFR2-mediated Rac1 activation. <b>2020</b> , 23, 685-698		20
333	Blockade of Platelet-Derived Growth Factor Signaling Inhibits Choroidal Neovascularization and Subretinal Fibrosis in Mice. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
332	Thermostable small-molecule inhibitor of angiogenesis and vascular permeability that suppresses a pERK-FosB/BosB-VCAM-1 axis. <b>2020</b> , 6, eaaz7815		6
331	Management of Fluid in Neovascular Age-related Macular Degeneration: To Mop it, to Dab it, or to Leave it?. <i>Retina</i> , <b>2020</b> , 40, 1451-1455	3.6	5
330	Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial. <b>2020</b> , 138, 835-842		1
329	Slowed Progression of Age-Related Geographic Atrophy Following Subthreshold Laser. <b>2020</b> , 14, 2983-2993		4

328	Trends in Real-World Neovascular AMD Treatment Outcomes in the UK. <b>2020</b> , 14, 3331-3342		13
327	Fibrotic Changes and Endothelial-to-Mesenchymal Transition Promoted by VEGFR2 Antagonism Alter the Therapeutic Effects of VEGFA Pathway Blockage in a Mouse Model of Choroidal Neovascularization. <b>2020</b> , 9,		7
326	Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up. <b>2020</b> , 2020, 3207614		3
325	Signalling, Metabolic Pathways and Iron Homeostasis in Endothelial Cells in Health, Atherosclerosis and Alzheimer's Disease. <b>2020</b> , 9,		5
324	Stem cell therapies for retinal diseases: from bench to bedside. <b>2020</b> , 98, 1347-1368		4
323	Effect of the Duration of Intraretinal or Subretinal Fluid on the Response to Treatment in Undertreated Age-Related Macular Degeneration. <b>2020</b> , 2020, 5308597		3
322	Fixed Regimen Treatment in Unselected Naïve Patients Cohort with Neovascular Age-Related Macular Degeneration. <b>2020</b> , 2020, 1-8		0
321	PREVALENCE AND RISK FACTORS FOR THE DEVELOPMENT OF PHYSICIAN-GRADED SUBRETINAL FIBROSIS IN EYES TREATED FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2020</b> , 40, 2285-2295	3.6	9
320	Fucoidans as Potential Therapeutics for Age-Related Macular Degeneration-Current Evidence from In Vitro Research. <b>2020</b> , 21,		4
319	Recent advances in intraocular and novel drug delivery systems for the treatment of diabetic retinopathy. <b>2021</b> , 18, 553-576		4
318	Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. <b>2020</b> , 21,		20
317	Hyaloid Vasculature as a Major Source of STAT3 (Signal Transducer and Activator of Transcription 3) Myeloid Cells for Pathogenic Retinal Neovascularization in Oxygen-Induced Retinopathy. <b>2020</b> , 40, e367-e379		0
316	Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat & Extend Anti-Vascular Endothelial Growth Factor Inhibitors. <b>2020</b> , 10, 8036		10
315	A Trinity regimen with aflibercept for treatment-naïve neovascular age-related macular degeneration: 2-year outcomes. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2020</b> , 258, 1663-1670	3.8	1
314	Type 1 Choroidal Neovascularization Evolution by Optical Coherence Tomography Angiography: Long-Term Follow-Up. <b>2020</b> , 2020, 4501395		1
313	Definition of indicators of appropriateness in the management of neovascular age-related macular degeneration: An expert opinion. <b>2020</b> , 30, 795-804		1
312	[Statement of the German Ophthalmological Society (DOG), the Retinological Society (RG) and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration : Status February 2020]. <b>2020</b> , 117, 746-754		2
311	Optical coherence tomography angiography markers associated with treatment response in neovascular age-related macular degeneration. <b>2021</b> , 31, 1192-1200		3

310	Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study. <i>Ophthalmology</i> , <b>2020</b> , 127, 1663-1673	7.3	10
309	Periostin and tenascin-C interaction promotes angiogenesis in ischemic proliferative retinopathy. <b>2020</b> , 10, 9299		3
308	Register your interest. <b>2020</b> , 48, 421-423		0
307	Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration. <b>2020</b> , 218, 225-241		12
306	Inhibiting NF- $\kappa$ B Signaling Activation Reduces Retinal Neovascularization by Promoting a Polarization Shift in Macrophages. <b>2020</b> , 61, 4		7
305	Three-Year Outcomes of Patients with Neovascular Age-Related Macular Degeneration Treated with Aflibercept under the National Health Insurance Program in Taiwan. <b>2020</b> , 2020, 4538135		2
304	Integrated bioinformatics analysis of aberrantly-methylated differentially-expressed genes and pathways in age-related macular degeneration. <i>BMC Ophthalmology</i> , <b>2020</b> , 20, 119	2.3	2
303	Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents. <b>2020</b> , 55, 286-292		4
302	Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration. <i>PLoS ONE</i> , <b>2020</b> , 15, e0229342	3.7	1
301	Ten-year outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular disease: A single-centre French study. <b>2020</b> , 48, 636-643		15
300	Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS Study. <b>2020</b> , 14, 1473-1481		0
299	Long-Term Visual/Anatomic Outcome in Patients with Fovea-Involving Fibrovascular Pigment Epithelium Detachment Presenting Choroidal Neovascularization on Optical Coherence Tomography Angiography. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
298	Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Results from real-life setting. <b>2021</b> , 31, 1940-1944		4
297	Eliminating Visual Acuity and Dilated Fundus Examinations Improves Cost Efficiency of Performing Optical Coherence Tomography-Guided Intravitreal Injections. <b>2020</b> , 219, 222-230		6
296	Mitochondrial dysfunction in age-related macular degeneration: melatonin as a potential treatment. <b>2020</b> , 24, 359-378		23
295	Brolucizumab: an evolution in treatment for neovascular age-related macular degeneration. <b>2020</b> , 15, 71-81		
294	Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration. <b>2020</b> , 2020, 8345850		2
293	Different conbercept injection strategies for the treatment of exudative age-related macular degeneration: A retrospective cohort study. <b>2020</b> , 99, e19007		5

292	Essential contribution of macrophage Tie2 signal mediated autophagy in laser-induced choroidal neovascularization. <b>2020</b> , 193, 107972		5
291	OCT Angiography Features of Neovascularization as Predictive Factors for Frequent Recurrence in Age-Related Macular Degeneration. <b>2020</b> , 213, 109-119		11
290	Ten-year outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration. <i>Eye</i> , <b>2020</b> , 34, 1888-1896	4.4	27
289	Oral Delivery of a Tetrameric Tripeptide Inhibitor of VEGFR1 Suppresses Pathological Choroid Neovascularization. <b>2020</b> , 21,		4
288	A G-Protein Coupled Receptor and Macular Degeneration. <b>2020</b> , 9,		4
287	Outcome of treatment for neovascular age-related macular degeneration by practice-based ophthalmologists compared with a macula clinic. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2020</b> , 258, 1405-1410	3.8	1
286	Leveraging Nuclear Receptors as Targets for Pathological Ocular Vascular Diseases. <b>2020</b> , 21,		6
285	Four-Year Outcome of Aflibercept Treatment-Naïve Patients for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting. <b>2020</b> , 2020, 7465270		5
284	Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2020</b> , 258, 1411-1417	3.8	3
283	Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) Trial. <i>Ophthalmology</i> , <b>2020</b> , 127, 1191-1200	7.3	8
282	Real-Life Data in the Treatment of Neovascular Age-Related Macular Degeneration: Results from the Imaculaweb Registry Evaluated in a Single Italian Medical Retina Center. <i>Ophthalmologica</i> , <b>2020</b> , 243, 453-460	3.7	10
281	Intraocular Pharmacokinetics of 10-fold Intravitreal Ranibizumab Injection Dose in Rabbits. <b>2020</b> , 9, 7		5
280	Risk factors for subretinal fibrosis after anti-VEGF treatment of myopic choroidal neovascularisation. <b>2021</b> , 105, 103-108		4
279	Macular atrophy development in neovascular age-related macular degeneration during first year of treatment: Incidence and risk factors. <b>2021</b> , 31, 521-528		0
278	Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration. <b>2021</b> , 65, 69-76		1
277	Simple Vision Function Tests that Distinguish Eyes with Early to Intermediate Age-related Macular Degeneration. <b>2021</b> , 28, 93-104		2
276	Statement of the German Ophthalmological Society (DOG), the German Retina Society (GRS), and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration : Status February 2020. <b>2021</b> , 118, 31-39		4
275	Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration: A Mixed-Methods Systematic Review. <i>Ophthalmology</i> , <b>2021</b> , 128, 234-247	7.3	25

274	A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States. <b>2021</b> , 223, 405-429		4
273	Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. <i>Progress in Retinal and Eye Research</i> , <b>2021</b> , 82, 100906	20.5	27
272	Long-term Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study: Report 1: Ten-Year, Real-World Outcomes. <i>Ophthalmology Retina</i> , <b>2021</b> , 5, 511-518	3.8	5
271	Revisiting the role of factor H in age-related macular degeneration: Insights from complement-mediated renal disease and rare genetic variants. <b>2021</b> , 66, 378-401		7
270	Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials. <b>2021</b> , 223, 338-347		1
269	Nonclinical Toxicology and Biocompatibility Program Supporting Clinical Development and Registration of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration. <b>2021</b> , 49, 663-672		4
268	Deep Learning-Based Detection of Endothelial Tip Cells in the Oxygen-Induced Retinopathy Model. <b>2021</b> , 49, 862-871		0
267	Dual-acting therapeutic proteins for intraocular use. <b>2021</b> , 26, 44-55		1
266	[Analysis of the "Portal" Care Model - Examination of the Outcome Quality of IVOM Therapy with Regard to Latency Periods in Exudative AMD]. <b>2021</b> , 238, 293-301		2
265	Pharmacotherapy of Age-Related Macular Degeneration. <b>2021</b> , 1-26		
264	Age-Related Macular Degeneration Revisited: From Pathology and Cellular Stress to Potential Therapies. <b>2020</b> , 8, 612812		13
263	Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study. <i>BMC Ophthalmology</i> , <b>2021</b> , 21, 58	2.3	1
262	Efficacy of Psychiatric Treatment to Treat a Specific Phobia of Intravitreal Injections in a Patient with Neovascular Age-Related Macular Degeneration. <b>2021</b> , 12, 48-56		1
261	Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration. <b>2021</b> , 15, 279-287		3
260	Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2021</b> , 259, 2085-2093	3.8	3
259	Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates. <b>2021</b> , 10, 34		5
258	[Anti-VEGF therapy of wet age-related macular degeneration: analysis of patients lost to follow-up]. <b>2021</b> , 137, 66-74		1
257	Ten-year outcome of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. <i>Indian Journal of Ophthalmology</i> , <b>2021</b> , 69, 2350-2354	1.6	3

256	Reactivation of CNV after Discontinuation of Bevacizumab Treatment of Age-Related Macular Degeneration. <i>Ophthalmologica</i> , <b>2021</b> , 244, 200-207	3.7	0
255	Identifying early symptoms of choroidal neovascularisation in second eyes of patients with unilateral wet age related macular degeneration using a telephone evaluation method. <i>Eye</i> , <b>2021</b> , 35, 3028-3034	4.4	
254	Reading Speed after Anti-vascular Endothelial Growth Factor Therapy in Patients with Wet Age-related Macular Degeneration. <b>2021</b> , 62, 68-76		
253	Emerging Therapies in Nonexudative Age-Related Macular Degeneration in 2020. <b>2021</b> , 10, 408-416		3
252	Longer-acting treatments for neovascular age-related macular degeneration-present and future. <i>Eye</i> , <b>2021</b> , 35, 1111-1116	4.4	8
251	Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD)-a meta-analysis. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2021</b> , 259, 2181-2192	3.8	5
250	Aflibercept for treatment-naïve diabetic macula oedema in a multi-ethnic population: Real-world outcomes from North West London. <i>PLoS ONE</i> , <b>2021</b> , 16, e0246626	3.7	1
249	Intraocular Injection of HyStem Hydrogel Is Tolerated Well in the Rabbit Eye. <b>2021</b> , 37, 60-71		2
248	Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
247	Treatment of Experimental Choroidal Neovascularization via RUNX1 Inhibition. <b>2021</b> , 191, 418-424		3
246	Repurposing bortezomib for choroidal neovascularization treatment via antagonizing VEGF-A and PDGF-D mediated signaling. <b>2021</b> , 204, 108446		0
245	Visual acuity and progression of macular atrophy in patients receiving intravitreal anti-VEGF for age-related macular degeneration. <b>2021</b> , 11206721211001708		0
244	Reliability of Retinal Pathology Quantification in Age-Related Macular Degeneration: Implications for Clinical Trials and Machine Learning Applications. <b>2021</b> , 10, 4		6
243	Loss of function of the carbon catabolite repressor CreA leads to low but inducer-independent expression from the feruloyl esterase B promoter in <i>Aspergillus niger</i> . <b>2021</b> , 43, 1323-1336		0
242	Three-year clinical and optical coherence tomography follow-up after stereotactic radiotherapy for neovascular age-related macular degeneration. <b>2021</b> , 66, 215-220		
241	Aflibercept in real-life for the treatment of age-related macular degeneration using a treat and extend protocol: The Armada study. <b>2021</b> , 11206721211005703		0
240	Current status of home monitoring technology for age-related macular degeneration. <b>2021</b> , 32, 240-246		1
239	Morphological features and prognostic significance of multilayered pigment epithelium detachment in age-related macular degeneration. <b>2021</b> ,		

238	Long-Term Visual Outcome in Inferior Posterior Staphyloma and Efficacy of Treatment for Complicated Choroidal Neovascularization. <b>2021</b> , 229, 152-159		0
237	Anti-VEGF Drugs Influence Epigenetic Regulation and AMD-Specific Molecular Markers in ARPE-19 Cells. <b>2021</b> , 10,		4
236	Visual Outcomes after Anti-VEGF Therapy for Exudative Age-Related Macular Degeneration in a Real-Life Setting. <b>2021</b> , 238, 396-402		0
235	New Drugs in the Pipeline for the Management of AMD.		
234	[Neovascular recurrences in 42 treatment-naive eyes with neovascular age-related macular degeneration (AMD) followed for over 2 years]. <b>2021</b> , 44, 626-631		
233	New insights into oxidative stress and immune mechanisms involved in age-related macular degeneration tackled by novel therapies. <b>2021</b> , 188, 108513		3
232	One year outcomes of treat and extend and pro re nata (PRN) treatment regimens with aflibercept for polypoidal choroidal vasculopathy. <b>2021</b> , 31, 2868-2875		1
231	Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series. <i>Eye</i> , <b>2021</b> ,	4.4	0
230	PIGMENT EPITHELIAL DETACHMENT IN AGE-RELATED MACULAR DEGENERATION: Long-Term Visual Acuity May Improve With Higher Injection Index. <i>Retina</i> , <b>2021</b> , 41, 2229-2235	3.6	0
229	Emerging therapies and their delivery for treating age-related macular degeneration. <b>2021</b> ,		6
228	Age-related macular degeneration. <b>2021</b> , 7, 31		71
227	Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles. <b>2021</b> ,		2
226	Evaluation of Long-Lasting Potential of Suprachoroidal Axitinib Suspension Via Ocular and Systemic Disposition in Rabbits. <b>2021</b> , 10, 19		0
225	A small molecular multi-targeting tyrosine kinase inhibitor, anlotinib, inhibits pathological ocular neovascularization. <b>2021</b> , 138, 111493		5
224	Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer. <b>2021</b> , 10,		4
223	Treat and extend paradigm in management of neovascular age-related macular degeneration: current practice and future directions. <b>2021</b> , 16, 267-286		
222	Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration. <b>2021</b> , 10, 30		3
221	Active Rap1-mediated inhibition of choroidal neovascularization requires interactions with IQGAP1 in choroidal endothelial cells. <b>2021</b> , 35, e21642		1



220	LONG-TERM COURSE AND VISUAL OUTCOMES OF PRECHOROIDAL CLEFT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY. <i>Retina</i> , <b>2021</b> , 41, 2436-2445	3.6	
219	Effect of Long-term Anti-VEGF Treatment on Viability and Function of RPE Cells. <i>Current Eye Research</i> , <b>2021</b> , 1-8	2.9	0
218	A comparative study between ranibizumab and its first biosimilar razumab in terms of efficacy and safety in DME, RVO and wet AMD associated with CNVM. <b>2021</b> , 7, 346-351		
217	Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry. <b>2021</b> , 49, 652-663		3
216	Microfluidic systems to examine Müller glia responses to anti-VEGF treatments. <i>Eye</i> , <b>2021</b> , 35, 3189-3191	4.4	
215	CM082, a novel VEGF receptor tyrosine kinase inhibitor, can inhibit angiogenesis in vitro and in vivo. <b>2021</b> , 136, 104146		1
214	Kinins and Their Receptors as Potential Therapeutic Targets in Retinal Pathologies. <b>2021</b> , 10,		4
213	A Proteogenomic Signature of Age-related Macular Degeneration in Blood.		
212	Predictive Factors for Long-Term Outcomes of Cataract Surgery in Patients Receiving Active Treatment for Neovascular Age-Related Macular Degeneration. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
211	Clinical efficacy of intravitreal corticoid as an adjunctive therapy to anti-VEGF treatment of neovascular age-related macular degeneration: a Meta-analysis. <b>2021</b> , 14, 1092-1099		0
210	Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option. <i>Journal of Immunology Research</i> , <b>2021</b> , 2021, 9945725	4.5	2
209	Results of patients with neovascular age-related macular degeneration managed by a treat-extend-stop protocol without recurrence. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2021</b> , 259, 3665-3673	3.8	1
208	The Challenges of Treating Neovascular Age-Related Macular Degeneration. <b>2021</b> ,		1
207	Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. <b>2021</b> , 11, 14623		0
206	Evolving Treatment Patterns and Outcomes of Neovascular Age-Related Macular Degeneration Over a Decade. <i>Ophthalmology Retina</i> , <b>2021</b> , 5, e11-e22	3.8	2
205	OUTCOMES IN PATIENTS RESUMING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOLLOWING TREATMENT DELAY DURING THE CORONAVIRUS-19 PANDEMIC. <i>Retina</i> , <b>2021</b> , 41, 2456-2461	3.6	3
204	Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration - Current Perspectives. <b>2021</b> , 15, 3351-3367		0
203	Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study. <i>BMC Ophthalmology</i> , <b>2021</b> , 21, 300	2.3	2

202	Central retinal thickness fluctuations in patients treated with anti-VEGF for neovascular age related macular degeneration. <b>2021</b> , 11206721211037820		0
201	Long-term outcomes of polypoidal choroidal vasculopathy in comparison with typical exudative age-related macular degeneration. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2021</b> , 1	3.8	0
200	The IL-23/IL-17 axis promotes the formation of retinal neovascularization by activating the NLRP3 inflammasome in macrophages in an experimental retinopathy mouse model. <b>2021</b> , 164, 803-816		1
199	Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials. <b>2021</b> , 65, 741-760		2
198	Immunological aspects of RPE cell transplantation. <i>Progress in Retinal and Eye Research</i> , <b>2021</b> , 84, 100950.5		12
197	Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. <i>Ophthalmology</i> , <b>2021</b> , 128, 1325-1336	7.3	11
196	Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapy. <b>2021</b> ,		2
195	Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis. <b>2021</b> , 27, 1260-1272		0
194	Vitreous Noise on Optical Coherence Tomography as an Early Finding of Brucizumab-Related Intraocular Inflammation. <b>2021</b> , 12, 797-803		1
193	LONG-TERM OUTCOMES OF BACILLARY LAYER DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Ophthalmology Retina</i> , <b>2021</b> ,	3.8	1
192	To the Question of Terminology, Expert Criteria for Evaluating the Effectiveness of Antiangiogenic Therapy and the Prevalence of Refractory Forms of Neovascular Age-Related Macular Degeneration. Review. <i>Oftalmologiya</i> , <b>2021</b> , 18, 389-398	0.3	0
191	Current Understanding of Polypoidal Choroidal Vasculopathy. <b>2021</b> , 61-71		
190	PDGF Receptor Alpha Signaling Is Key for Müller Cell Homeostasis Functions. <b>2021</b> , 22,		2
189	Principal Cause of Poor Visual Acuity after Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 23. <i>Ophthalmology Retina</i> , <b>2021</b> , 5, 23-31	3.8	5
188	Clinical efficacy and safety of Razumab (CESAR) study: Our experience with the world's first biosimilar Ranibizumab. <i>Indian Journal of Ophthalmology</i> , <b>2021</b> , 69, 347-351	1.6	6
187	Extracellular vesicles mediate cellular interactions in renal diseases-Novel views of intercellular communications in the kidney. <b>2021</b> , 236, 5482-5494		3
186	Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives. <b>2021</b> , 13,		25
185	Four-year outcomes of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a treat-and-extend regimen in Japanese patients. <b>2021</b> , 13, 2515841420984586		2

184	Current Management of Age-Related Macular Degeneration. <b>2021</b> , 1256, 295-314		1
183	Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration. <b>2021</b> , 15, 189-194		1
182	RPE and the Vascular Endothelial Growth Factor. <b>2020</b> , 85-99		1
181	Angiogenesis-Based Therapies for Eye Diseases. <b>2017</b> , 259-297		2
180	Restoring Physiologic Barriers Against Neovascular Invasion. <b>2015</b> , 87-95		1
179	Preclinical challenges for developing long acting intravitreal medicines. <b>2020</b> , 153, 130-149		9
178	Systemic counterregulatory response of angiopoietin-2 after aflibercept therapy for nAMD: a potential escape mechanism. <i>Acta Ophthalmologica</i> , <b>2021</b> , 99, e869-e875	3.7	1
177	A novel device for rapid, safe and precise delivery of intravitreal injections. <b>2019</b> , 5, 8-12		1
176	Anti-VEGF therapy: higher potency and long-lasting antagonism are not necessarily better. <b>2019</b> , 129, 3032-3034		17
175	Recent developments in the treatment of age-related macular degeneration. <b>2014</b> , 124, 1430-8		118
174	VEGF regulates local inhibitory complement proteins in the eye and kidney. <b>2017</b> , 127, 199-214		82
173	ATN-161 as an Integrin $\beta_1$ Antagonist Depresses Ocular Neovascularization by Promoting New Vascular Endothelial Cell Apoptosis. <b>2018</b> , 24, 5860-5873		8
172	Diabetes mellitus and risk of age-related macular degeneration: a systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2014</b> , 9, e108196	3.7	41
171	Fundus autofluorescence of retinal angiomatous proliferation. <i>PLoS ONE</i> , <b>2020</b> , 15, e0243458	3.7	2
170	Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study. <i>PLoS ONE</i> , <b>2020</b> , 15, e0244183	3.7	2
169	[Long-term outcomes of anti-angiogenic therapy for macular neovascular disorders]. <b>2016</b> , 132, 76-84		1
168	Six-year outcomes in neovascular age-related macular degeneration with ranibizumab. <b>2017</b> , 10, 81-90		12
167	Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes. <b>2020</b> , 15, 341-350		2

166	Calcitriol and non-calcemic vitamin D analogue, 22-oxacalcitriol, attenuate developmental and pathological choroidal vasculature angiogenesis and. <b>2020</b> , 11, 493-509	4
165	Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models. <b>2015</b> , 6, 10563-76	20
164	Cholesterol homeostasis, macrophage malfunction and age-related macular degeneration. <b>2018</b> , 6, S55	3
163	Treat and Extend Dosing Regimen with Anti-vascular Endothelial Growth Factor Agents for Neovascular Age-related Macular Degeneration. 1, 1	8
162	Accuracy of fundus autofluorescence imaging for the diagnosis and monitoring of retinal conditions: a systematic review. <b>2016</b> , 20, 1-108	5
161	Effects of the COVID-19 Pandemic on Anti-vascular Endothelial Growth Factor Treatment in China. <b>2020</b> , 7, 576275	19
160	Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration. <b>2015</b> , 46, 542-9	5
159	Predictors of Macular Atrophy Detected by Fundus Autofluorescence in Patients With Neovascular Age-Related Macular Degeneration After Long-Term Ranibizumab Treatment. <b>2016</b> , 47, 224-31	12
158	Influence of Retinal Pathology on the Reliability of Macular Thickness Measurement: A Comparison Between Optical Coherence Tomography Devices. <b>2017</b> , 48, 319-325	7
157	36-Month Evaluation of Intravitreal Aflibercept Injection for Wet Age-Related Macular Degeneration in Patients Previously Treated With Ranibizumab or Bevacizumab. <b>2018</b> , 49, 179-185	1
156	Effects of Brimonidine on Retinal Pigment Epithelial Cells and Müller Cells Exposed to Amyloid-Beta 1-42 Peptide In Vitro. <b>2018</b> , 49, S23-S28	6
155	Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System. <b>2018</b> , 49, 913-917	10
154	Classification of Strokes in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor. <b>2019</b> , 50, e140-e157	9
153	Tissue plasminogen activator-assisted vitrectomy for submacular hemorrhage due to age-related macular degeneration. <i>Indian Journal of Ophthalmology</i> , <b>2017</b> , 65, 482-487	1.6 5
152	Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents for Ocular Vascular Diseases: Clinical Practice Guideline. <b>2018</b> , 13, 158-169	12
151	Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration. <b>2017</b> , 47, 133-137	7
150	Risk-based Algorithm-guided Treatment Protocol for the Management of Neovascular Age-related Macular Degeneration. <b>2019</b> , 49, 258-269	1
149	Age-related macular degeneration treatment in the era of molecular medicine. <b>2014</b> , 4, 130	1

148	Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin. <b>2020</b> , 9,		22
147	Efficacy of Anti-Vascular Endothelial Growth Factor Treatment in Neovascular Age-Related Macular Degeneration and Systemic Cardiovascular Risk Factors. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
146	The Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment. <i>Ophthalmologica</i> , <b>2021</b> ,	3.7	3
145	Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab. <b>2021</b> , 15, 4073-4079		0
144	Updates in deep learning research in ophthalmology. <b>2021</b> , 135, 2357-2376		3
143	Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update. <b>2021</b> , 35, 673-692		2
142	Pro-inflammatory activation changes intracellular transport of bevacizumab in the retinal pigment epithelium in vitro. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2021</b> , 1	3.8	1
141	Clinical symptoms and signs. <b>2014</b> , 20-36		
140	Anti-Angiogenic Gene Therapy: Basic Science and Challenges for Translation into the Clinic. <b>2016</b> , 173-188		
139	Context for Protons as Adjunctive Therapy in Neovascular Age-Related Macular Degeneration: A Review. <b>2016</b> , 2, 555-569		
138	Paradigm of Susceptibility Genes in AMD and PCV. <b>2017</b> , 169-192		1
137	Unique Genetic Signatures in Asian Age-Related Macular Degeneration: An Opportunity for Drug Development. <b>2017</b> , 497-507		
136	Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab. <b>2017</b> , 10, 423-426		1
135	Induction of vascular endothelial growth factor receptor expression in human umbilical vein endothelial cells after repeated bevacizumab treatment. <b>2017</b> , 10, 1064-1068		1
134	Our experience in visual functions' improvement in patients with wet age-related macular degeneration at switching from one anti-VEGF agent to another. <b>2017</b> , 10, 67-73		0
133	[Prognostic factors of antiangiogenic therapy response in neovascular macular degeneration]. <b>2018</b> , 134, 48-55		0
132	Treated exudative CNV: short-term and long-term real-life evolution. <b>2018</b> , 60,		
131	Long-Term Visual Outcomes in Patients with Neovascular AMD Who Exhibited Visual Acuity of 0.1 or Worse at 5th Injection. <b>2018</b> , 3, 64-70		

130	Comment on "Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration". <b>2018</b> , 11, 1884-1886		1
129	Calcitriol and Non-Calcemic Vitamin D Analogue, 22-Oxacalcitriol, Attenuate Developmental and Pathological Ocular Angiogenesis Ex Vivo and In Vivo.		
128	Clinical Course of Patients with Neovascular Age-related Macular Degeneration Who Experienced Visual Deterioration after Treatment despite Initially Good Visual Acuity. <b>2019</b> , 4, 10-16		
127	Clinical Management of Myopia in Adults: Treatment of Myopic CNV. <b>2020</b> , 271-288		
126	Recent Developments in Maculopathy. <b>2020</b> , 141-163		
125	Importance of Treatment Duration: Unmasking Barriers and Discovering the Reasons for Undertreatment of Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration. <b>2021</b> , 15, 4317-4326 <sup>3</sup>		
124	Mitophagy Protects the Retina Against Anti-Vascular Endothelial Growth Factor Therapy-Driven Hypoxia Hypoxia-Inducible Factor-1 $\beta$ Signaling. <b>2021</b> , 9, 727822		0
123	TANDEM TRIAL: a factorial randomised controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands. <b>2020</b> , 5, e000588		
122	[Anti-VEGF-therapy of fibrovascular and serous-vascularized pigment epithelial detachment in neovascular AMD : A retrospective five-year-analysis]. <b>2021</b> , 118, 1255-1263		1
121	Side Effects of Brolucizumab. <b>2021</b> , 16, 670-675		0
120	Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis. <b>2021</b> , 10, 5		0
119	Changes in Systemic Levels of Vascular Endothelial Growth Factor After Intravitreal Injection of Aflibercept or Brolucizumab for Neovascular Age-Related Macular Degeneration. <i>Retina</i> , <b>2021</b> ,	3.6	0
118	Association of Smoking, Alcohol Consumption, Blood Pressure, Body Mass Index, and Glycemic Risk Factors With Age-Related Macular Degeneration: A Mendelian Randomization Study. <b>2021</b> ,		2
117	Stellungnahme der DOG, der RG und des BVA zur Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration. <b>2020</b> , 237, 995-1003		1
116	Long-term Outcomes of Treat and Extend Regimen of Anti-vascular Endothelial Growth Factor in Neovascular Age-related Macular Degeneration. <b>2020</b> , 15, 331-340		1
115	Reliability of retinal pathology quantification in age-related macular degeneration: Implications for clinical trials and machine learning applications.		
114	Endothelial NADPH oxidase 4 mediates vascular endothelial growth factor receptor 2-induced intravitreal neovascularization in a rat model of retinopathy of prematurity. <b>2014</b> , 20, 231-41		53
113	Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis). <b>2014</b> , 112, 142-59		31

112	Modern Strategies to Save Sight in Diabetes. <b>2016</b> , 113, 372-377		
111	Use of Fundus Autofluorescence Combined with Optical Coherence Tomography for Diagnose of Geographic Atrophy in Age-Related Macular Degeneration. <b>2019</b> , 8, 298-305		2
110	Voluntary Exercise Suppresses Choroidal Neovascularization in Mice. <b>2020</b> , 61, 52		0
109	Clinical Outcomes of Aflibercept Treatment for Treatment-naive Exudative Age-related Macular Degeneration. <b>2021</b> , 6, 99-109		
108	Exploring Consensus on Preventive Measures and Identification of Patients at Risk of Age-Related Macular Degeneration Using the Delphi Process. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	0
107	The Influence of COVID-19 on the Stability of Patients with Neovascular Age-Related Macular Degeneration with Different Treatment Regimens. <b>2021</b> , 1		2
106	Retinal Diseases Regulated by Hypoxia-Basic and Clinical Perspectives: A Comprehensive Review. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
105	Role of inflammasome activation in neovascular age-related macular degeneration. <b>2021</b> ,		0
104	Treatment patterns and outcomes with anti-vascular endothelial growth factor agents for wet age-related macular degeneration in clinical practice: an analysis of the IRIS Registry. <b>2021</b> ,		1
103	Morphologic and Microvascular Differences Between Macular Neovascularization With and Without Subretinal Fibrosis. <b>2021</b> , 10, 1		2
102	Can the Onset of Neovascular Age-Related Macular Degeneration Be an Acceptable Endpoint for Prophylactic Clinical Trials?. <i>Ophthalmologica</i> , <b>2021</b> , 244, 379-386	3.7	
101	Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape.. <b>2021</b> , 8,		4
100	Discovery and Development of the Quininib Series of Ocular Drugs.. <b>2022</b> , 38, 33-42		
99	Baseline predictors for subretinal fibrosis in neovascular age-related macular degeneration.. <b>2022</b> , 12, 88		1
98	Vitreous microparticles contain apoptotic signals suggesting a diabetic vitreopathy.. <b>2022</b> , 15, 89-97		
97	Treatment of macular diseases: an overview of key randomized clinical trials. <b>2022</b> , 14, 137-148		0
96	The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review.. <b>2022</b> , 108910		1
95	Real-world effectiveness of screening programs for age-related macular degeneration: amended Japanese specific health checkups and augmented screening programs with OCT or AI.. <b>2022</b> , 66, 19-32		0

94	Update of application of olfactory ensheathing cells and stem cells/exosomes in the treatment of retinal disorders.. <b>2022</b> , 13, 11		0
93	Gene-Based Therapeutics for Inherited Retinal Diseases.. <b>2021</b> , 12, 794805		4
92	Transcriptomic analysis of choroidal neovascularization reveals dysregulation of immune and fibrosis pathways that are attenuated by a novel anti-fibrotic treatment.. <b>2022</b> , 12, 859		0
91	Disease Progression Pathways of Wet AMD: Opportunities for New Target Discovery.. <b>2022</b> ,		0
90	Automated evaluation of retinal pigment epithelium disease area in eyes with age-related macular degeneration.. <b>2022</b> , 12, 892		0
89	Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept.. <b>2022</b> , 8, 11		
88	Treatment Outcome of Wet Age-Related Macular Degeneration Management in Thailand: A Retrospective Real-World Study (TOWER Study).. <b>2022</b> , 11, 739		1
87	A validated analysis pipeline for mass spectrometry-based vitreous proteomics: new insights into proliferative diabetic retinopathy. <b>2021</b> , 18, 28		2
86	Risk factors for emerging intraocular inflammation after intravitreal brolocizumab injection for age-related macular degeneration. <i>PLoS ONE</i> , <b>2021</b> , 16, e0259879	3.7	5
85	Intraocular Cytokine Changes in Patients with Polypoidal Choroidal Vasculopathy Treated with Ranibizumab. <b>2022</b> , 63, 166-174		
84	SAFETY AND THERAPEUTIC EFFECTS OF ORALLY ADMINISTERED AKST4290 IN NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.. <i>Retina</i> , <b>2022</b> , 42, 1038-1046	3.6	1
83	Progression of age-related macular degeneration in eyes with abnormal fundus autofluorescence in a Japanese population: JFAM study report 3.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0264703	3.7	
82	A systematic review of clinical practice guidelines for myopic macular degeneration.. <b>2022</b> , 12, 04026		1
81	Masking of macular neovascular membranes by subretinal hyperreflective material on optical coherence tomography angiography.. <b>2022</b> , 11206721221085396		
80	Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options.. <b>2022</b> , 16, 917-933		2
79	Long term retinal morphology and functional associations in treated neovascular age-related macular degeneration: findings from the IVAN trial.. <i>Ophthalmology Retina</i> , <b>2022</b> ,	3.8	0
78	Correlation between Fundus Autofluorescence and En Face Optical Coherence Tomography Measurements of Geographic Atrophy.. <i>Ophthalmology Retina</i> , <b>2022</b> ,	3.8	0
77	The value of handholding during intravitreal injections.. <i>Irish Journal of Medical Science</i> , <b>2022</b> ,	1.9	



76	Anti-angiogenic properties of rapamycin on human retinal pericytes in an in vitro model of neovascular AMD via inhibition of the mTOR pathway.. <i>BMC Ophthalmology</i> , <b>2022</b> , 22, 138	2.3	0
75	Longer Term Visual Outcomes in Neovascular AMD, Diabetic and Vein Occlusion Related Macular Edema: Clinical Outcomes in 130,247 Eyes.. <i>Ophthalmology Retina</i> , <b>2022</b> ,	3.8	2
74	Macrophage elastase (MMP12) critically contributes to the development of subretinal fibrosis.. <i>Journal of Neuroinflammation</i> , <b>2022</b> , 19, 78	10.1	1
73	Short- and Long-Term Visual Outcomes in Patients Receiving Intravitreal Injections: The Impact of the Coronavirus 2019 Disease (COVID-19)-Related Lockdown.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	1
72	Comparison of visual outcomes of polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration-up to 10 years of follow-up.. <i>Acta Ophthalmologica</i> , <b>2022</b> ,	3.7	0
71	Long-term characteristics of exudative age-related macular degeneration in Japanese patients.. <i>PLoS ONE</i> , <b>2021</b> , 16, e0261320	3.7	0
70	Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization.. <i>Biology</i> , <b>2021</b> , 10,	4.9	2
69	Long-term Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: An Open-label 12-month Extension to the CANTREAT Study.. <i>Ophthalmologica</i> , <b>2021</b> ,	3.7	
68	Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis.. <i>Journal of Immunology Research</i> , <b>2022</b> , 2022, 6004047	4.5	1
67	Table_1.DOCX. <b>2020</b> ,		
66	Trends, geographical variation and factors associated with the use of anti-VEGF intravitreal injections in Portugal (2013-2018): a retrospective analysis of administrative data.. <i>BMJ Open</i> , <b>2022</b> , 12, e055478	3	0
65	Pharmacotherapy of Age-Related Macular Degeneration. <b>2022</b> , 3619-3644		
64	COVID-19 Pandemic Lockdowns Impact on Visual Acuity of Neovascular AMD Patients: A Large cohort.. <i>Retina</i> , <b>2022</b> ,	3.6	
63	Analysis of the Long-term visual Outcomes of ForeseeHome Remote Telemonitoring - The ALOFT study.. <i>Ophthalmology Retina</i> , <b>2022</b> ,	3.8	0
62	Adherence to the Mediterranean-Style Eating Pattern and Macular Degeneration: A Systematic Review of Observational Studies. <i>Nutrients</i> , <b>2022</b> , 14, 2028	6.7	1
61	nAMD: optimization of patient care and patient-oriented information with the help of an internet-based survey.. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2022</b> ,	3.8	
60	The Role of Retinal Plasticity in the Formation of Irreversible Retinal Deformations in Age-Related Macular Degeneration.. <i>Current Eye Research</i> , <b>2022</b> , 1-7	2.9	
59	IL-33 enhances Jagged1 mediated NOTCH1 intracellular domain (NICD) deubiquitination and pathological angiogenesis in proliferative retinopathy.. <i>Communications Biology</i> , <b>2022</b> , 5, 479	6.7	0

58	The negative impact of COVID-19 pandemic on age-related macular degeneration patients treated with intravitreal bevacizumab injections. <i>International Ophthalmology</i> ,	2.2	1
57	Patterns of treatment discontinuation in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. <i>Indian Journal of Ophthalmology</i> , <b>2022</b> , 70, 2065	1.6	1
56	Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. <i>Science Translational Medicine</i> , <b>2022</b> , 14,	17.5	1
55	Evaluation of OCT biomarker changes in treatment-naïve neovascular AMD using a deep semantic segmentation algorithm.		0
54	A proteogenomic signature of age-related macular degeneration in blood. <i>Nature Communications</i> , <b>2022</b> , 13,	17.4	1
53	Towards the Development of Longer and More Efficacious Therapies for Wet and Dry Age-related Macular Degeneration. <b>2022</b> , 16, 30		
52	15 years of anti-VEGF treatment for nAMD: success or failure or something in between?. <i>Eye</i> ,	4.4	1
51	Bioengineering approaches for modelling retinal pathologies of the outer blood-retinal barrier. <i>Progress in Retinal and Eye Research</i> , <b>2022</b> , 101097	20.5	
50	Study of the Level of Pro- and Antiangiogenic Growth Factors in Vitreous Fluid in Neovascular Age-Related Macular Degeneration on the Background of Treatment. <i>Oftalmologiya</i> , <b>2022</b> , 19, 368-377	0.3	
49	The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study. <b>2022</b> , 17, e0271999		
48	Ethnic differences on long term outcomes of polypoidal choroidal vasculopathy after predominantly bevacizumab monotherapy. <b>2022</b> , 22,		
47	Recent Advances in Age-Related Macular Degeneration Therapies. <b>2022</b> , 27, 5089		2
46	A Real-World, Multicenter, 6-Month Prospective Study in Greece of the Effectiveness and Safety of Ranibizumab in Patients with Age-Related Macular Degeneration Who Have Inadequately Responded to Aflibercept: The "ELEVATE" Study. Volume 16, 2579-2593		
45	Properties of Cephalopod Skin Ommochromes to Inhibit Free Radicals, and the Maillard Reaction and Retino-Protective Mechanisms in Cellular Models Concerning Oxidative Stress, Angiogenesis, and Inflammation. <b>2022</b> , 11, 1574		
44	Animal Models of Choroidal Neovascularization: A Systematic Review. <b>2022</b> , 63, 11		0
43	Placental growth factor stabilizes VEGF receptor-2 protein in retinal pigment epithelial cells by downregulating glycogen synthase kinase 3 activity. <b>2022</b> , 102378		
42	Effectiveness of anti-VEGF treatment in wet Age-related Macular Degeneration; an evaluation of silent reading performance with eye movement analysis.		
41	Destructive inflammatory reaction after an autologous retinal pigment epithelium and choroid transplantation: no detection of an auto-immune response. <b>2022</b> , 12,		

40	Long-term persistence to aflibercept therapy among treatment-naïve patients with exudative age-related macular degeneration in a universal health care system: A retrospective study.	
39	Long-term persistence with aflibercept therapy among treatment-naïve patients with exudative age-related macular degeneration in a universal health care system: a retrospective study. <b>2022</b> , 22,	0
38	Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy. Volume 16, 3395-3400	1
37	Effectiveness of bevacizumab step therapy for neovascular age-related macular degeneration.	0
36	Long-term results (60 months) of anti-VEGF therapy of macular diseases in real clinical practice. Part 1. <b>2022</b> , 15, 11-17	1
35	Review of fibrosis in neovascular age-related macular degeneration. <b>2022</b> ,	0
34	Single-Cell Transcriptome of Wet AMD Patient-Derived Endothelial Cells in Angiogenic Sprouting. <b>2022</b> , 23, 12549	0
33	Macular Atrophy Incidence, Progression, and Visual Acuity Effects in 5-Year Treatment of Neovascular Age-Related Macular Degeneration. <b>2022</b> , 53, 546-552	0
32	Clinical Phenotypes of Patients with Neovascular Age-Related Macular Degeneration and Poor Response to Aflibercept Treatment. <b>2022</b> , 19, 647-657	0
31	Combination of AIBP, apoA-I, and Aflibercept Overcomes Anti-VEGF Resistance in Neovascular AMD by Inhibiting Arteriolar Choroidal Neovascularization. <b>2022</b> , 63, 2	1
30	Exploring the pathogenesis of age-related macular degeneration: A review of the interplay between retinal pigment epithelium dysfunction and the innate immune system. 16,	2
29	Utilization of ferulic acid in <i>Aspergillus niger</i> requires the transcription factor FarA and a newly identified Far-like protein (FarD) that lacks the canonical Zn(II) <sub>2</sub> Cys <sub>6</sub> domain. 3,	0
28	Long-term treatment outcomes after bevacizumab therapy for macular neovascularization in Caucasian patients with high myopia.. <b>2022</b> , Publish Ahead of Print,	0
27	Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy. <b>2022</b> , 58, 1703	0
26	Treating Retinal Diseases by Optical Coherence Tomography Alone During COVID-19 Lockdown.	0
25	Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan.	1
24	Visual Acuity in Patients Requiring Intravitreal Injections: Short-Term and Long-Term Effects of Delay in Care. 247412642211366	0
23	Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy. <b>2022</b> , 22,	0

- 22 Progress of iPS cell-based transplantation therapy for retinal diseases. ○
- 21 Biofuels as Economic Security for the Poor. **2022**, 201-218 ○
- 20 Choroidal Neovascular Membranes in Retinal and Choroidal Tumors: Origins, Mechanisms, and Effects. **2023**, 24, 1064 ○
- 19 Treatment Strategies for Chorioretinal Vascular Diseases: Advantages and Disadvantages of Individualised Therapy. 91-98 ○
- 18 Do anti-VEGFs used in the ophthalmic clinic cause Müller glial cell stress?. **2023**, 78, 100161 ○
- 17 Bruchâ Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration. **2023**, 12, 2870 ○
- 16 Interaction of High-Molecular Weight Fucoidan from Laminaria hyperborea with Natural Functions of the Retinal Pigment Epithelium. **2023**, 24, 2232 ○
- 15 Seven-year outcome after 1-year fixed regimen of intravitreal aflibercept injections followed by pro re nata treatment for neovascular age-related macular degeneration. ○
- 14 Effective treatment of retinal neovascular leakage with fusogenic porous silicon nanoparticles delivering VEGF-siRNA. **2022**, 17, 2089-2108 ○
- 13 Antiangiogenic therapy for ocular diseases: Current status and challenges. **2023**, 2, ○
- 12 Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. **2023**, 21, ○
- 11 Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration. Volume 17, 657-665 ○
- 10 Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. **2023**, ○
- 9 Influence of Clinical and Genetic Factors on the Progression of Age-Related Macular Degeneration: A 3-Year Follow-Up. **2023**, 12, 1963 ○
- 8 Persistence of vascular empty sleeves in choroidal neovascularization after VEGF therapy in both animal models and humans. ○
- 7 MMP9-Responsive Graphene Oxide Quantum Dot-Based Nano-in-Micro Drug Delivery System for Combinatorial Therapy of Choroidal Neovascularization. 2207335 ○
- 6 Long-Term Visual Outcomes in Neovascular Age-Related Macular Degeneration Eyes With Baseline Macular Atrophy on Anti-Vascular Endothelial Growth Factor Treatment. **2023**, 54, 223-230 ○
- 5 Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration. **2023**, 23, ○

- 4 Effects of acupuncture on age-related macular degeneration: A systematic review and meta-analysis of randomized controlled trials. **2023**, 18, e0283375 ○
- 3 Fibrosis in neovascular age-related macular degeneration: A review of definitions based on clinical imaging. **2023**, ○
- 2 Anti-inflammatory properties of antiangiogenic fucoidan in retinal pigment epithelium cells. **2023**, 9, e15202 ○
- 1 Blockade of Annexin A2 Prevents Early Microvasculopathy in Murine Models of Diabetic Retinopathy. **2023**, 64, 33 ○